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ABSTRACT 
Devika Chawla: Cannabis Use and Reproductive Health: An Analysis of Time Trends and 
Adverse Birth Outcomes  
(Under the direction of Julie L. Daniels) 
 
Cannabis is the most commonly used illicit drug among populations of reproductive age 
in the United States (U.S.) [2-4]. Despite changing policies and attitudes, little is known about 
how patterns of cannabis use are changing among populations of reproductive age, or about how 
cannabis might affect fetal development.  
Understanding trends requires careful consideration of underlying demographic factors, 
such as age, generation, and period effects due to significant events such as legalization. 
Therefore, we first aim to estimate age, period, and cohort effects of past-month cannabis use 
among U.S. populations of reproductive age from 2002-2014 using the National Survey of Drug 
Use and Health (NSDUH, n=534,679). As policies and patterns of cannabis use continue to 
change, health effects are increasingly important to understand. Animal studies suggest cannabis 
affects sperm quality and may alter DNA packaging, but effects on fetal development remain 
unknown. Therefore, we secondly aim to estimate effects of paternal preconception cannabis use 
on structural birth defects in the National Birth Defects and Prevention Study (NBDPS, 
n=34,320).  
Past-month cannabis use among U.S. populations of reproductive age increased from 
9.2% in 2002 to 12.3% in 2014. Distinct age, period, and cohort effects were observed, though 
age effects were largest in magnitude. In NBDPS, cannabis use during the 3-month 
preconception period was reported for 8.8% of control-fathers. After adjustment for confounders, 
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paternal cannabis use was associated with gastroschisis (aOR: 1.23, 95% CI: 1.00, 1.52), and 
meaningfully associated with diaphragmatic hernia (aOR: 1.33, 95% CI: 0.99, 1.80), cleft lip 
alone (aOR: 1.23, 95% CI: 0.95, 1.60), and hypoplastic left heart syndrome (aOR: 1.38, 95% CI: 
0.99, 1.92).  
Past-month cannabis use is prevalent and increasing among men and women of 
reproductive age. While distinct age, period, and cohort effects are at play, age remains the 
strongest correlate of past-month use. Moreover, our results may suggest increased risk of some 
birth defects following paternal preconception cannabis use, though studies with better exposure 
measurement are needed. Future research is needed to understand how paternal cannabis use 
affects fetal development, especially in light of changing cannabis policies and documented 
increases in prevalence of use. 
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CHAPTER 1: SPECIFIC AIMS 
Cannabis is the most commonly used illicit drug among men and women of reproductive 
age in the United States [2, 3]. As of 2015, an estimated 1 in 5 young adults (aged 18-25) were 
current users of cannabis [8]. Prevalence of current cannabis use has steadily increased from 
16% in 2004 to 20% in 2015 in this age group [8]. Moreover, cannabis attitudes among young 
adults continue to move towards greater acceptance; the percentage of teenagers who perceive 
“great risk from regular use” has significantly decreased in the past decade [9, 10]. Policies on 
cannabis legality are also rapidly changing. To date, 24 states have legalized medical use, and 
four states and the District of Columbia have legalized recreational use, and six states have 
legislation pending [11]. Despite changing policies and attitudes, little is known about what 
drives these changes in prevalence of cannabis use over time. Identifying drivers of time 
trends can shed light on social-cultural changes in cannabis use, providing useful information for 
policy-makers. 
Understanding how trends change over time requires careful consideration of underlying 
factors that contribute to observed trends, such as shifts in the population distribution of age, 
period effects due to significant events (such as legalization), and generational effects. Age-
period-cohort (APC) analysis is a method specifically designed to examine time trends and the 
underlying factors that contribute to them. Four APC analyses on cannabis use in adult 
populations have been published, but all but one examined data only through 2009. Cannabis 
laws and social norms have changed drastically since then, so it is essential to understand drivers 
of time trends in the past seven years. Additionally, no APC analyses to date have focused on 
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individuals of reproductive age [12, 13]. The three published studies evaluated ever/never use in 
the past 12 months, but not more recent use, which is more biologically relevant for cannabis’ 
effect on reproductive health. Therefore, I aim to conduct an APC analysis of past-month 
cannabis use among men and women of reproductive age from 2002 to 2014 using the 
National Survey of Drug Use and Health (NSDUH), a nationally representative annual 
survey of drug use conducted by the Department of Health and Human Services.  
To parse out the independent age, period, and cohort effects that contribute to the 
observed trends in cannabis use, we plan to conduct sub-analyses to better characterize these 
patterns. First, to better understand the user population, we plan to estimate socio-demographic 
risk factors for current cannabis use in populations of reproductive age. Second, we will evaluate 
how the APC effects differ by gender. We know that men are more likely to use cannabis than 
women [14]. However, recent trends show that cannabis use is increasing faster among women 
than among men, and little research has shown why. Therefore, we hypothesize that the period 
effects (changing policies and social norms) are stronger for women than for men. Third, because 
social norms surrounding cannabis use are rapidly changing, we plan to evaluate time trends in 
risk perception of cannabis use in populations of reproductive age.  
As policies and attitudes towards cannabis use change rapidly, it is essential to 
understand how cannabis use patterns may impact health.  Because legalization may 
increase use among men and women of reproductive age, the reproductive health effects 
are especially important to understand. Animal studies have shown that THC – the main 
psychoactive component of cannabis – crosses the placenta. Epidemiologic studies suggest that 
prenatal exposure is associated with fetal growth restriction, specific birth defects, increased 
likelihood of neonatal intensive care, and changes in brain morphology [6, 15-19]. While more 
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research is needed to understand the effects of maternal exposure, we know even less about the 
potential reproductive effects of paternal exposure. THC has been shown to reduce sperm 
concentration and alter sperm motility in human semen samples [20]. A recent epidemiologic 
study of Danish men aged 18-28 showed significant differences in sperm quality measures 
between regular marijuana smokers (more than once a week) versus non-smokers (n=1215) [21]. 
In addition to altering sperm concentration and morphology, THC has been shown to damage 
DNA packaging during spermatogenesis [22]. While the effect of cannabis on sperm quality 
has been demonstrated, very little research has focused on the potential effects of paternal 
preconception cannabis use on embryonic development. Since cannabis affects sperm quality, 
it warrants investigation as a potential risk factor for birth defects [5, 23]  
Major birth defects, defined as a structural malformation with a significant impact on the 
health and development of a child, are the leading cause of infant mortality and lifelong 
disability [24, 25]. While some genetic and environmental risk factors have been identified, little 
is known about the etiology of most birth defects. Though most research has focused on maternal 
risk factors, epidemiologic investigations have shown that paternal exposures during the 
preconception period can increase risk of birth defects [26-29]. 
Only three studies to date have investigated the association of paternal cannabis use and 
birth defects. Two have suggested an increased risk for cardiac-related birth defects among 
infants of fathers with preconception paternal cannabis use [30, 31]. One study reported a null 
association between preconception cannabis use and neural tube defects [32]. However, all three 
studies had insufficient control of confounding and lacked clinical verification of the reported 
birth defects among offspring.  Moreover, no studies have evaluated an association of paternal 
cannabis use and other types of birth defects. Therefore, I aim to estimate the association 
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between paternal preconception cannabis use and risk of major structural birth defects in 
the National Birth Defects and Prevention Study (NBDPS) – the largest case-control study 
of birth defects in the U.S. with rigorous clinical outcome verification and classification.  
Cannabis is an increasingly prevalent exposure among men and women of reproductive 
age, yet little is known about patterns of use or effects on reproductive health in this population. 
Twenty-five U.S. states have already legalized cannabis either medically or recreationally, and 
other states are currently considering similar laws. As policies and social norms surrounding 
cannabis continue to rapidly evolve, we must gain a better understanding of how cannabis affects 
reproductive health. Therefore, our specific aims are as follows: 
Aim 1: Conduct an age-period-cohort analysis of recent (past 30 days) cannabis use among men 
and women of reproductive age from 2002 to 2014 using a nationally-representative data source. 
• Sub Aim 1a: Estimate risk factors for recent cannabis use in this population. 
• Sub Aim 1b: Quantify age, period, and cohort effects of past-month cannabis use. 
• Sub Aim 1c: Evaluate if age, period, cohort effects differ by gender. 
Aim 2: Estimate the association between paternal 3-month preconception cannabis use and 
prevalence of major birth defects.  
• Sub Aim 2a: Estimate prevalence of cannabis use among men in preconception period. 
• Sub Aim 2b: Quantify crude and adjusted effect estimates for paternal cannabis use and 
specific birth defect phenotypes.  
• Sub Aim 2c: Evaluate potential bias due to exposure misclassification using a 
probabilistic bias analysis approach.  
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CHAPTER 2: BACKGROUND & SIGNIFICANCE 
2.1 Aim 1 
2.1.1 Patterns of cannabis use in the U.S.  
Cannabis, also known as marijuana, marihuana, or weed, is any preparation of the 
cannabis sativa plant, which is generally used by smoking, vaping, or eaten as a food or extract 
[33]. Cannabis is the most commonly used illicit drug among men and women of reproductive 
age in the United States [2, 3]. As of 2015, an estimated 1 in 5 young adults (aged 18-25) were 
current users of cannabis [8].  Approximately 44% of U.S. adults reported ever using cannabis 
[34]. Since legal, social, and cultural norms surrounding cannabis use are rapidly changing, 
patterns of use are likely to change as well. Here, we provide a brief overview of how cannabis is 
consumed, demographic patterns of cannabis use in the United States today, and how patterns of 
use are changing over time.  
Cannabis can be consumed in a few different ways. The most common method of 
consumption is smoking the cannabis plant in the form of a joint, bowl, or pipe. Less frequently, 
bongs, water pipes, or hookah devices are used [35]. Cannabis can also be vaporized, or “vaped”, 
where active ingredients are released into a smokeless vapor, then inhaled using a vaporizer or e-
cigarette device. Some studies suggest that vaping is on the rise, due to increased prevalence of 
e-cigarettes in the U.S. and perceptions that vaping is healthier than smoking cannabis [36, 37]. 
Tetrahydrocannabinol (THC), the main psychoactive component of cannabis, can be extracted in 
oil form, called “hash”. Extracts of the cannabis plant can also be prepared in various types of 
food or drinks, called “edibles”. While no consistent estimate is apparent in the literature, a 
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recent study using social media data found that approximately 16% of cannabis users consume 
edibles [35]. A relatively new method of consuming cannabis is using butane hash oil, 
colloquially known as “dabs”, which involves butane extraction of the THC from flowering 
cannabis [38]. The resulting substance is much more THC-concentrated than tradition forms of 
cannabis. Though “dabbing” is not common and understudied, it appears to be on the rise in the 
United States [38].  
Cannabis use is an ancient practice, and socio-cultural norms surrounding cannabis use 
vary greatly across cultures. Archeologic sources date cannabis use back to 2000 B.C. in India 
and China, where it was used for medicinal or spiritual purposes [39]. In fact, the THC-induced 
cannabinoid activation is mediated by a compound called anandamide, which comes from the 
Sanskrit word ‘anande’, which means ‘joy, bliss, delight’. The practice of using cannabis for 
medicinal, spiritual, and recreational purposes has since spread to the rest of the world – 
cannabis is by far the most widely cultivated, trafficked, and abused illicit drug in the world [40].  
Individuals generally use cannabis for one of two reasons: (1) medical, including but not 
limited to pain management, appetite management during cancer treatment, post-traumatic stress 
disorder (PTSD), irritable bowel syndrome (IBS), or self-diagnosed conditions, or (2) 
recreational, i.e. to experience a high [41]. A majority of cannabis users report recreational 
reasons, though approximately 10% report medical reasons only, and approximately 36% of 
users report both medical and recreational reasons [35]. Characteristics of cannabis use differ for 
medical and recreational users. Individuals using cannabis for medical purposes are more likely 
to vape or eat, while recreational cannabis users are more likely to smoke [42]. Medical users 
tend to use cannabis more frequently than recreational users, though frequency of use varies 
greatly [42, 43]. Medical users are more likely to concurrently use opioids, both prescribed and 
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non-prescribed, as compared to recreational users [43]. Women are more likely to use cannabis 
medically as compared to recreationally [43]. In states where medical cannabis is legal, medical 
users are more likely to obtain cannabis from dispensaries, where cannabis is regulated and doses 
are labeled. Potency and strain of cannabis vary greatly, and recreational users are often unaware 
of the potency of the cannabis they consume [44].  
Cannabis use is considerably more prevalent among young adults (age 18-25), as 
compared to all other age groups in the United States [2]. Men are more likely than women to 
use cannabis [2, 45, 46]. Frequency of cannabis use varies by state, likely due to the different 
legal status in various states. According to the 2016 SAMSHA report, the states with the highest 
proportion of past-month cannabis users among ages 12 and older are Vermont (17%), Oregon 
(16%), Alaska (16%), and Colorado (16%), and Rhode Island (15%) [47]. Racial and socio-
economic status (SES) patterns are less clear. Most studies suggest that Whites have the highest 
past-year cannabis use prevalence, followed by African-Americans, then Hispanics [43, 45]. 
However, most nationally-representative studies on drug use exclude incarcerated populations 
[48, 49]. Since African-Americans are more likely than Whites to be incarcerated for cannabis 
use, available demographic data on racial patterns might be under-representing African-
Americans.  In some study populations, cannabis users tend to have higher educational 
attainment as compared to non-users, while the opposite trend is observed in other study 
populations [43, 46, 50] . Racial and SES characteristics of cannabis users are perhaps more 
nuanced than these studies reflect, or perhaps they depend on geographic location and study 
population.  
2.1.2 Time trends of cannabis use in the U.S.  
 How have cannabis use patterns among U.S. men and women changed over time? There 
are a few ways to answer this question, which we will briefly review here. The most 
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comprehensive study of youth drug trends in the U.S. in the Monitoring the Future (MTF) study, 
which surveys high school students across the nation annually. From 1976 to 2013, the MTF 
study found that current cannabis use 
slowly declined from the 1970s to the 
1990s, but has steadily increased from 
the 1990’s until now (see Figure 2.1) 
[51]. By 2010, the rate of cannabis use 
exceeded that of cigarette use among 
U.S. youth [1]. More recent trends 
from MTF (past 10 years) suggest that 
cannabis use is steadily increasing 
among high school students (Figure 
2.2) [1].  
The most comprehensive study 
of drug use in the general population 
is the National Drug Use and Health 
Survey (NSDUH), a nationally-
representative annual survey among non-institutionalized adults age 12 and older [2]. The most 
recent NSDUH report shows a steady increase in current cannabis use from 2002 to 2015. Since 
cannabis use rates differ by age, NSDUH presents their time trends stratified by age group (see 
Figure 2.2). Cannabis use is highest among the 18-25 age group, and rates in all groups have 
been steadily increasing since 2005. Though qualitative, NSUDH trends suggest a recent spike in 
reported cannabis use from 2012 to 2015, driven by the ’26 or older’ age group. Broadly, both 
Figure 2.1. Trends of recent cannabis use among male and 
female high school students in Monitoring the Future Study, 
1975-2013 [1] 
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MTF and NSDUH show a steady increase in current cannabis use in the past 15 years among 
men and women of reproductive age.  
 
Figure 2.2. Trends of recent cannabis use among U.S. individuals (age 12 and older) from the 
National Survey of Drug Use and Health, 2002-2015 
 
2.1.3. Age, period, and cohort effects 
When measuring time trends of cannabis use, a big analytic challenge is the parsing out 
changes over time into the differential contributions of three time-related effects: age effects, 
period effects, and cohort effects [52]. These three effects represent distinct phenomena of 
interest, which we will contextualize with our outcome – cannabis use. Age effects represent the 
effect of an individual’s age at the time of observation on the outcome [52]. In other words, how 
does one’s age influence likelihood to use cannabis? Period effects represent the influence of the 
time period of measurement of the outcome [52]. For example, how does the socio-cultural 
context of the 1994 influence likelihood of cannabis use, as compared to the socio-cultural 
context of the 2014 Period effects especially of interest, due to the recent changes in recreational 
and medical cannabis legality, and shifting social attitudes towards cannabis [53]. Cohort effects 
represent the influence in the year of birth or some other shared life events for a set of 
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individuals. These are also known as “generational effects.” For example, how does being born 
in the 1960’s influence likelihood of cannabis use, compared to being born in the 1990’s? Age, 
period, and cohort are distinct important effects of interest for cannabis use, but time trends 
reported in repeated cross-sectional designs – like the MTF or NSDUH graphs above (Figures 
2.1 and 2.2) – fail to show these distinct effects. To parse out time trends in these three effects, a 
specific type of analysis is needed: age-period-cohort (APC) analysis [52].  
2.1.3.1 Current literature  
 To date, five APC analyses on various aspects of cannabis use have been published. 
These four studies are summarized below in Table 2.1.  
Johnson et al. analyzed age, period, and cohort effects of “marijuana incidence”, which 
they define as they age at first marijuana use. Authors found that period effects became weaker 
over the course of the study period (1961-1990), which they suggest is due to the anti-drug 
policies of the 1980s. They also found that cohort effects became stronger over the course of the 
study period, especially for women. While this study focused on the age at which individuals 
first try marijuana, it did not report APC effects related to recent marijuana use or among 
individuals older than 24 years of age. Cohort effects, may differ for age at first use compared to 
recent use.  Further investigation is needed regarding trends in recent use among individuals of 
reproductive age, which would be most important for policy and public health messaging around 
the prevention of adverse birth outcomes.   
Kerr et al. conducted an APC analysis on cannabis use prevalence, which is defined as 
ever/never use in the past 12 months. To our knowledge, this was the first published APC 
analysis of prevalence cannabis use. Using “ever/never use in the past 12 months” is the most 
common way to operationalize prevalent cannabis use in the literature, and is used by three out 
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of four of the APC analyses. Authors found that overall time trends differed by sex; cannabis use 
decreased for men, but remained stable for women, during the study period (1984-2000). 
Authors also found strong age and cohort effects. However, this analysis relied on only four 
study years to extrapolate trends for a 16-year period, thus limiting the validity of the trends. An 
APC analysis is strengthened by having more consistent time points of measurement, like annual 
or semi-annual measurement [52]. Another limitation of this study is the data source. The 
National Alcohol Study (NAS), as its name suggest, was primarily designed to ascertain accurate 
estimates of alcohol use, and was not specifically designed to ask about illicit drug use.  The 
NAS has face-to-face interviews, and unlike other drug use surveys, lacks specific techniques for 
making respondents feel safe and comfortable reporting illegal activities. This data ascertainment 
method likely increased measurement error, with more people underreporting their cannabis use 
as compared to anonymous drug use surveys. 
  
1
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Table 2.1. Overview of four age-period-cohort analyses on marijuana-related outcomes  
Author Year  Outcome  Data source Study population Main findings 
Johnson 2000 age at first 
marijuana 
use 
National Household 
Surveys on Drug 
Abuse  
US men and women 
aged 10-24, interviewed 
between 1961-1990 
- Period effects decreased, cohort effects increased over 
course of study period.  
- Cohort effects were stronger for women. 
- Authors suggest that anti-drug policies of 1980s explain 
decreasing period effects.  
Kerr 2007 ever/never 
use in past 
12 months 
National Alcohol 
Surveys  
US men and women 
aged 18-80, interviewed 
1984, 1990, 1995, and 
2000 
- Marijuana use trends differed by sex; trends were 
decreasing for men; stable for women. 
- Birth cohorts born after 1945 have higher rates of 
marijuana use. 
- Age effects strongly predicted use, especially for women. 
- Period effects were stronger for men.  
Piontek 2011 ever/never 
use in past 
12 months 
German 
Epidemiological 
Survey of Substance 
Abuse 
German men and 
women aged 18-65, 
interviewed some years 
between 1990-2009 
- Age was strongest predictor of cannabis use. Prevalence 
peaks in young adulthood and decreasing with age. 
- Counter to hypothesis, cohort effects were not significant. 
- Authors suggest “cannabis boom” of early 2000s Europe 
was mostly experimental use, thus not reflected in past-12-
month use variable.  
Miech 2012 ever/never 
use in past 
12 months 
National Survey on 
Drug Use and Health 
US men and women 
aged 15-64, interviewed 
some years between 
1985-2009  
 - Age effects are strong for both men and women. 
- Cohort effects were strong for older individuals, weaker 
for younger individuals. 
- Recent increase in marijuana use due to period effects.  
- Period effects becoming stronger for all ages/cohorts. 
Kerr 2017 ever/never 
use in past 
12 months 
National Alcohol 
Surveys 
US men and women 
aged 18-80, interviewed 
1984-2015 
- Age effects were strong, especially at younger ages and 
especially among men 
- Cohort and period effects were moderate but increasing  
- Cannabis policy changes did not significantly increase use 
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Piontek et al. conducted an APC analysis on prevalent cannabis use, also defined as 
ever/never use in the past 12 months. However, this study was conducted in a German study 
population. Authors found strong age effects, which is consistent with results found by Kerr et al. 
and Meich et al. Authors were specifically interested in the “cannabis boom” of the early 2000s 
in Europe and expected to see cohort or period effects that reflect that boom. Authors did not 
find significant age and period effects, and suggest that their outcome measure (ever/never use in 
the past 12 months) was not sensitive enough to capture these effects. A major limitation of this 
study is changing age eligibility over the study period (1990-2009). The upper age limit was 39 
in 1990, 59 in 1995, and 64 in 2006 onwards. Since the age distribution is artificially different 
across the study period, the ability of the APC analysis to parse out separate age, period, and 
cohort effects is limited. Additionally, the socio-cultural norms surrounding cannabis use likely 
differ between German and U.S. populations, making it difficult to compare APC analyses from 
these two countries. 
Meich et al. is the most recent APC analysis on prevalent cannabis use, both in terms of 
publishing date (2012) and study years (1985-2009). It is the only APC analysis that includes 
U.S. cannabis use data from the 21st century. Similar to previous APC analyses, authors also 
define their outcome as ever/never use in the past 12 months. This analysis uses data from the 
National Study on Drug Use and Health (NSDUH), a nationally-representative study of drug use 
in the U.S. (which we plan to use for Aim 1). Like previous studies, authors found a strong age 
effect. But, authors also found an increase in marijuana use prevalence for all birth cohorts, and 
suggest that period effects were growing stronger. This finding was unique from previous APC 
analysis, and perhaps reflects the more recent trends of reduced stigma, lower risk perception, 
and loosening of cannabis policies in the U.S.  
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Most recently, Kerr et al. conducted an age-period-cohort analysis of past-year cannabis 
use among US adults age 18 and older using the National Alcohol Surveys from 1984-2015 [54]. 
Authors found strong age effects at younger (18-30) ages, and age effects were slightly stronger 
in magnitude for women as compared to men.  This study was able to utilize a longer study 
period than previous study years and identified that cohort effects were small but increased with 
later birth cohorts, especially for women. Period effects were moderately strong and increased in 
recent years (2005-2015). However, when authors examine specific cannabis policy changes 
(legalization of: recreational use, medical marijuana grown at home, medical marijuana sold at 
dispensaries), no significant effects on past-year use were observed. Authors suggest the strong 
period effects but non-significant policy change effects are due to changing social norms and risk 
perceptions that drive both trends in use and policy-change, so the policies themselves do not 
causally result in increased use.  
In summary, there is a small literature on age, period, and cohort effects of cannabis use 
in the US, though these trends are of major public health significance. A major limitation of the 
literature is the limited number of analyses with data from 2000 onwards, despite the rapidly 
changing socio-cultural norms, laws, and use patterns of cannabis in this century. The one 
analysis with data since 2012 – Kerr et al. 2017 – found that period effects grew stronger in the 
past decade, though they did not use a nationally-representative data source. Therefore, this 
literature needs updated, rigorous APC analyses from nationally-representative data to accurately 
reflect drivers of more recent time trends in cannabis use.  
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2.2 Aim 2 
2.2.1 Cannabis use and reproductive health 
 The primary psychoactive element of cannabis – delta-9-tetrahydrocannabinol (THC) – 
interacts with the body’s endocannabinoid system by stimulating cannabinoid receptors, 
specifically CB1 and CB2 receptors [55]. Cannabinoid receptors are highly expressed in the 
nervous system, which explains the short-term neurophysiological effects of cannabis use, like 
altered senses (i.e. feeling “high”), changes in mood, pain modulation, and impaired memory 
[33]. However, cannabinoid receptor are also located in other parts of the human body, including 
the testis, vas deferens, uterus, and ovaries [55-59]. Because of THC’s strong role in activating 
cannabinoid receptors in reproductive organs, animal studies and a small epidemiologic literature 
have investigated the effect of cannabis use on various aspect of reproductive health. Results 
differ by sex and are summarized below.  
2.2.1.1 Women 
The effect of cannabis use on female reproductive health can be viewed in two contexts: 
preconception health and pregnancy health. Little is known about the effects of cannabis use on 
preconception health among women, but animal studies have found that chronic use can disrupt 
the menstrual cycle, suppressing oogenesis, and impair embryo implantation [60, 61]. In human 
studies, cannabis use has been shown to disrupt menstrual cycles, specifically by suppressing 
luteinizing hormone levels during the luteinizing phase, increasing risk of anovulatory cycles, 
affecting embryo implantation [61-64]. Findings from both animal and human studies suggest 
that acute THC suppresses the release of gonadotropin-releasing hormone (GnRH) and 
thyrotropin-releasing hormone (TRH) from the hypothalamus, thus preventing the release of 
menstruation-regulating hormones [62]. Additionally, a recent study in mice found that prenatal 
cannabis exposure at low doses reduced birthweight in offspring, higher proportion of male pups, 
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and reduced maternal weight gain [65]. In summary, the literature on the effects of cannabis use 
on preconception reproductive health in women is small, but animal models show consistent 
effects on various aspects of menstruation and suggest biologic pathways for adverse effects on 
fertility.  
While our study aims do not directly address cannabis use during pregnancy, 
understanding effects during pregnancy are of interest because (1) women who use cannabis 
prior to getting pregnancy are more likely to use cannabis during pregnancy as compared to non-
users, and (2) pregnancy is an extremely sensitive window of exposure, both for the mother and 
the infant. Endocannabinoid signaling is involved in fertilization, implantation, embryo 
development, and early pregnancy maintenance [66]. Cannabinoid receptors have recently been 
identified in human uterus tissue, and THC exerts a relaxant effect on oxytocin-induced human 
myometrial contractility – an important factor in labor induction [67]. Animal studies have 
shown that THC crosses the placenta, achieving concentrations in the fetus that are consistent 
with that of the mother [68]. Additionally, a recent 2018 showed that THC inhibited the 
migration of human amniotic epithelial cells, which may affect amniotic fluid development and 
spontaneous preterm birth risk [69]. A handful epidemiologic studies have investigated the 
effects of cannabis use during pregnancy and birth or infant outcomes, with mixed results. A 
recent meta-analysis suggests that prenatal cannabis exposure is associated with fetal growth 
restriction and increased likelihood of neonatal intensive care, but not with preterm birth [6, 15, 
16]. A 2017 study from the NICHD Stillbirth Collaborative Research network showed that 
biomarker-validated prenatal cannabis use was not associated with small-for-gestational-age or 
spontaneous preterm birth, but was associated with neonatal mortality [70]. Recent 
epidemiologic studies suggest that prenatal cannabis exposure may alter brain morphology and 
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neurodevelopment in the infant [17, 71, 72]. After adjustment, periconceptional cannabis use was 
associated with increased odds of specific birth defects phenotypes (namely anencephaly and 
gastroschisis) in the National Birth Defects Prevention Study [16]. In summary, the animal and 
epidemiologic literature suggests some adverse effects of cannabis use during pregnancy, but 
more research is needed to fully understand the range and severity of these effects. 
2.2.1.2 Men 
A growing epidemiologic literature has shown that current cannabis use has adverse 
effects on various aspects of semen quality. A 2014 case-control study on modifiable risk factors 
for poor sperm morphology found that cannabis use in the 3 months prior to sample collection 
significantly increased risk for poor sperm morphology (OR: 1.94; 95% CI: 1.05, 3.60) [73].  A 
2015 review article summarizes the consistent effects of cannabis on reducing sperm count, 
motility, viability, and morphology [74]. Most notably, a recent epidemiology study of 1215 
young Danish men found that regular marijuana use significantly lowered sperm concentration 
and sperm count [21]. In response to this study, Eisenberg et al. published a commentary in the 
American Journal of Epidemiology stressing the need for more research on the effect of cannabis 
on male reproductive health [75]. Though cannabis has negative effects on sperm quantity, a 
2017 study showed it was positive associated sexual frequency among U.S. men and women 
[76], so it presumably does not affect sexual function.  
Both CB1 and CB2 receptors are present in human sperm [74]. Human studies have 
shown that CB1 activation increases the proportion of immobile sperm, and CB2 activation 
increases the proportion of “sluggish” sperm, providing biologic evidence that cannabis affects 
sperm motility [77]. Figure 2.3 depicts the location of CB1 and CB2 receptors in human sperm 
cells. Additionally, mouse studies have shown that CB1 receptors – which are significantly 
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activated by THC – influence chromatin remodeling in sperm, suggesting that cannabis has 
potential epigenetic effects on sperm cells [22].  
 
Figure 2.3. Location and influence of CB1 (cannabinoid receptor 1) and CB2 (cannabinoid 
receptor 2) on human sperm function [35] 
 
While the effects of chronic cannabis use on the endocannabinoid system and sperm 
quality measures have been demonstrated, the effects on reproductive outcomes are less 
established. While clinic-based studies suggest that men with fertility issues are more likely to 
use cannabis, no population-based time-to-pregnancy studies have published on paternal 
cannabis use [78, 79]. Two case-control study of cardiac heart defects (CHDs) suggest increased 
risk among men who use cannabis 3 months prior to conception; these studies are discussed in 
more detail in section 2.2. [30, 31]. Some epidemiologic studies suggest a potential mutagenic 
effect of cannabis on male reproductive organs. Specifically, a recent meta-analysis suggests that 
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weekly cannabis use increases risk of testicular cancer (summary OR: 2.59, 95% CI: 1.60, 4.19) 
[55]. Despite the strong evidence and biologic mechanism for the effect of cannabis on sperm 
quality, very few epidemiologic studies to date have investigated preconception cannabis use and 
adverse reproductive outcomes.  
2.2.1.3 Summary 
There is a strong literature on the biologic mechanisms for cannabis’s effect on both 
female and male reproductive health. Less is known about the effects on female preconception 
health, though animal studies suggest cannabis interferes with regular menstrual function. More 
is known about the adverse effects on male reproductive health, namely on sperm count, 
motility, and morphology. Recent epidemiologic population-based studies have confirmed these 
effects. Animal studies suggest that cannabis has epigenetic effects on sperm, but very few 
studies have investigated the effects of preconception cannabis use on fertility or infant 
outcomes. In summary, cannabis use has some proven and some hypothesized effects of 
reproductive health, but little is known about the effect of preconception cannabis use on 
offspring development. 
2.2.2 Brief epidemiology of birth defects 
Birth defects are the leading cause of infant mortality and lifelong disability [25, 80]. The 
Centers for Disease Control and Prevention (CDC) estimate that birth defects affect every 1 in 33 
babies born in the United States [25, 80]. Babies born with a birth defect are five times more 
likely to die in the first year of life, as compared to healthy babies [80]. Additionally, caring for 
children with birth defects can place significant emotional and financial strains on families and 
caretakers [81]. A recent US study showed birth defects led to more than 130,000 hospital stays 
during a single year, result in $2.6 billion in hospital costs alone [82]. Although some genetic 
and environmental risk factors have been identified, little is known about the etiology of most 
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birth defects [83]. Identifying modifiable risk factors for birth defects is essential for reducing 
the incidence of these common, costly, and critical conditions. 
Animal studies have shown that most structural birth defects develop early in 
embryogenesis, typically during the first 10 weeks of pregnancy [84, 85]. Most defects occur in 
isolation, affecting only one organ system. Multiple defects – when an infant has a defect in 
more than one organ system – account for approximately a quarter of all birth defects, though 
this varies by phenotype [86]. While some birth defects have a genetic cause, most defects 
cannot be explained by a single gene or chromosomal abnormality – these are called ‘non-
chromosomal defects’. The etiology of non-chromosomal defects are likely a complex interplay 
between genetic, epigenetic, and environmental factors [84]. 
There are hundreds of birth defect phenotypes that are clinically and etiologically 
heterogeneous. For reasons described elsewhere, Aim 2 will focus on 21 specific subtypes of 
structural birth defects. Here we provide a brief background on some (but not all) of the birth 
defect phenotypes included in the Aim 2 analysis: (1) hypospadias, (2) congenital heart defects 
(CHDs), (3) oral clefts, and (4) gastroschisis.  These phenotypes are common, non-chromosomal 
defects with unknown etiologies.  
2.2.2.1 Hypospadias 
Hypospadias is a birth defect in male infants where the urethra is not located at the tip of 
the penis. During fetal development, this abnormal urethral development occurs during weeks 8 
to 14 post-conception [87]. Severity of this defect can vary; minor defects are considered “first 
degree”, while more sever defects are considered “second degree” or “third degree” [88]. There 
are three subtypes of hypospadias; classification depends on the location of the opening of the 
urethra. Boys with hypospadias often have problems with urinating, and sometimes have 
difficulty performing sexual intercourse later in life [87]. Hypospadias is one of the most 
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common birth defects in the U.S., affecting approximately 1 in every 150 male live births (64 
cases per 10,000 male live births) [89]. Prevalence of hypospadias seems to be increasing in 
certain populations, though this is debated in the literature [90-92].  
Etiology of hypospadias is largely unknown, though some genetic and environmental risk 
factors have been identified. Some studies suggest genetic variation, specifically on androgen 
receptor and estrogen receptor genes, may contribute to risk of hypospadias [91]. Exposure to 
endocrine-disrupting chemicals appears to be a risk factor [93, 94]. A recent meta-analysis 
showed that maternal occupational exposure to pesticides was associated with increased odds of 
hypospadias (pooled RR=1.4; 95% CI: 1.0, 1.8) [95]. Paternal occupational exposure was also 
associated with increased odds of hypospadias (pooled RR=1.2; 95% CI: 1.0, 1.4), suggested a 
paternally-mediated pathway for hypospadias is plausible.  
2.2.2.2 Congenital heart defects 
Congenital heart defects (CHDs) are conditions present at birth that can affects the 
structure or functioning of an infant’s heart. CHDs are the most common type of birth defects 
[96, 97]. CHDs are the most common type of birth defect at time of live birth, with an estimated 
prevalence of 1 case per 100 live births, though severity of these defects range widely [98]. Note 
that true incidence in utero is unknown due to missing data on pregnancy loss potentially due to 
CHDs [99]. While infant mortality rates remain high (approximately 25% of infants born with a 
severe CHD die in the first year of life), advancing medical treatment has allowed infant with 
CHDs to live longer and healthier lives [96]. Most infants born with severe CHDs need surgery 
or other procedures in their first year of life [96]. Among those who survive to adulthood, 
considerable morbidity persists for patients with CHDs as compared to patients with healthy 
hearts [100]. Prevalence of some subtypes, specifically atrial and ventricular septal defects, has 
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steadily increased in the past 30 years, while prevalence of other subtypes have remained stable 
[101].  
Etiology remains largely unknown, though specific genetic causes have been identified 
for specific CHD phenotypes. Less is known about non-inherited causes, but established risk 
factors include maternal rubella, pre-gestational diabetes, exposure to thalidomide, vitamin A 
cogeners, and phenylketonuria [97]. A recent review paper on CHDs identified these exposures 
as areas for future investigation: peri-conceptional multivitamin intake, maternal drug exposures, 
environmental exposures, and paternal exposures [97]. 
CHDs are a broad category with clinically and etiologically heterogeneous sub-types. 
Here we briefly outline the levels of CHD classification relevant for this project. The selected 
CHDs for this analysis fall in two broad categories: (1) septal defects and (2) obstructive defects. 
Atrial septal defects (ASDs) and ventricular septal defects (VSDs) fall under the category of 
septal CHDs. Left ventricular outflow tract obstruction (LVOTO) and right ventricular outflow 
tract obstruction (RVOTO) fall under the category of obstructive defects [98]. Septal defects 
generally indicate a “hole” exists between two chambers of the heart, so oxygen-rich blood can 
leak into oxygen-poor regions, and vice versa. ASDs indicate a hole in the atrial chambers, and 
VSDs indicate a hole in the ventricular chambers (Sadler book) [102]. Obstructive defects 
generally include defects of blood flow. LVOTO refers to defects that obstruct blood flow out of 
the left ventricular chamber, and RVOTO refers to defects that obstruct blood flow out of the 
right ventricular chamber [102]. Figure 2.4 below outlines this categorical hierarchy for the 
selected CHDs for this analysis. Note that many more sub-types exist within the CHD category; 
we focus on these selected phenotypes for reasons described in the Aim 2 Methods section.  
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Figure 2.4. Hierarchy of selected congenital heart defect (CHD) categories 
 
2.2.2.3 Oral clefts 
Oral clefts are defects of the infant’s lip or mouth. Oral clefts include two types of 
defects: (1) cleft lip and (2) cleft palate. During fetal development, the lip forms between the 4th 
and 7th week of pregnancy and the palate forms between the 6th and 9th week of pregnancy 
[103]. Oral clefts have an estimated prevalence of 16 cases per 10,000 live births, or 1 in 600 live 
births [89] . Infants born with cleft lip and/or cleft palate often have issues with feeding, 
speaking, and hearing; they are at higher risk for dental problems and ear infections. Children 
might need continued services, like special dental care or speech therapy [104]. Surgery to repair 
cleft lip and/or palate is usually recommended in the first 18 months of life. With treatment, most 
children with oral cleft are able to lead a healthy life, though some dental and speech issues may 
persist [103, 104].  
Causes remain unknown, though a complex etiology involving gene-by-environment 
interactions is suggested [105]. Identified risk factors include: cigarette smoking during 
pregnancy, maternal diabetes prior to pregnancy, and specific medication use during first 
trimester [103, 106]. A recent meta-analysis found that older paternal age (>40 years) was 
Seleted CHDs
Septal
ASD
VSD
Obstructive
LVOTO
RVOTO
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associated with increased odds of having a newborn with cleft palate (OR:1.58, 95% CI: 1.15, 
2.17), suggesting that paternal factors may play a role in oral cleft etiology [107].  
2.2.2.4 Gastroschisis 
 Gastroschisis is an abdominal wall defect that results in the infant’s intestines exiting the 
body through the belly button. This defects results from aberrations in early fetal development 
where the infant’s abdominal wall does not form correctly [108, 109]. Gastroschisis is an 
extremely adverse birth defect that results in increased risk of medical complications and infant 
mortality [110]. Severity of the defect varies, since the size of the hole and organs impact differ 
in each case. Generally, babies born with gastroschisis need surgery to place abdominal organs 
back inside the body. They also need specific treatments, such as antibiotics to prevent infection 
and an IV to provide essential nutrients, during the neonatal period [109].  
Reports from multiple surveillance systems show that prevalence has been increasing 
since the 1980s [109, 110]. While increase in prevalence are documented among all ages groups, 
the increase is particularly striking among young (<20) mothers. Young maternal age was first 
documented as a risk factor for gastroschisis in the 1970s. A study in Norway reported an 
independent association with paternal age, after accounting for confounding by maternal age 
[111]. While etiology of gastroschisis remains unknown, the most recent MMWR suggests that 
“epidemiologic patterns indicate that lifestyle behaviors, environmental exposures, or other risk 
factors disproportionately affecting young women might play a role” [110]. More research is 
needed to understand etiology of gastroschisis and explain the recent spikes in prevalence.  
2.2.3 Paternal exposures and birth defects 
While most research on birth defects etiology focuses on the mother, recent 
epidemiologic investigations have shown that paternal exposures during the preconception 
period can increase risk of birth defects [29, 112]. Certain paternal occupations – notably 
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painters, chemical workers, agricultural workers, and janitors – are associated with increased 
odds of birth defects [113, 114]. A small literature has examined the association between 
paternal exposure to organic solvents and neural tube defects. A meta-analysis of these studies 
found that paternal exposure to organic solvents is associated with an increased risk of any 
neural tube defect (summary OR: 2.18, 95% CI: 1.52-3.11) [115]. While the exact mechanisms 
behind these paternal effects is unknown, these studies suggest a morphologic and/or mutagenic 
effect on the sperm, which then increases risk of a birth defect. This growing literature shows the 
plausibility of paternal exposures during the preconception causing particular birth defects, 
potentially mediated through sperm quality. 
Additional evidence of male-mediated teratogenicity comes from the childhood cancer 
literature. Animal studies have shown that male rodents exposed to chemical carcinogens in the 
weeks prior to mating result in significant increases in tumor incidence in progeny [29]. 
Epidemiologic studies have consistently found that paternal occupational exposures to metals are 
associated with increased risk of specific childhood cancers in offspring [29]. While childhood 
cancer is a distinct outcomes from birth defects, they may share a causal mechanism of male-
mediated epigenetic effects and are therefore of interest. 
Two studies have examined preconception paternal cigarette smoking and risk of birth 
defects. A 1992 study from China found that paternal cigarette smoking increased risk of 
anencephaly and spina bifida. A 2013 study from China found that preconception paternal 
cigarette smoking increased certain subtypes of cardiac heart defects (CHDs) among offspring 
[116].  A recent molecular review paper suggests this effect could be mediated by the adverse 
effects of polycyclic aromatic hydrocarbons (PAHs) on spermatocytes. Briefly, the PAHs in 
cigarettes can impact aryl hydrocarbon receptor (AHR) activation, which leads to oxidative 
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stress-mediated DNA damage in sperm [117]. While cigarette smoking and cannabis smoking 
are different exposures with different biologic components, the fact that paternal cigarette 
smoking increases risk of specific birth defects warrants investigation of cannabis smoking as a 
potential teratogen.  
2.2.4 Association between paternal cannabis use and major structural birth defects 
Since cannabis affects the way genetic material is transferred from father to developing 
fetus, it warrants investigation as a potential risk factor for birth defects. Figure 2.5 depicts the 
conceptual diagram for Aim 2, which is focused on estimating the effect of 3-month paternal 
preconception cannabis use and risk of major structural birth defects. Here, we summarize the 
previous literature on this association and explain how our proposal addresses gaps in this 
literature.  
 
Figure 2.5. Conceptual diagram for potential effects of paternal cannabis on fetal development 
 
2.2.4.1 Current literature 
Three studies have addressed some aspect of the paternal cannabis use – birth defects 
association, summarized below in Table 2.2.
  
2
7
 
Table 2.2. Overview of three studies of preconception paternal cannabis use and risk of specific birth defect 
Author Year  Outcome  Exposure Data 
source 
Study population Main findings 
Shaw  1996 Neural tube 
defects (NTDs) 
Face-to-face 
maternal 
interview; 
mothers asked 
about paternal 
drug use 3 months 
prior to pregnancy 
California 
Birth 
Defects 
Monitoring 
Program  
Cases: Singleton fetuses and live-
born infants diagnosed with NTD 
(includes fetal deaths) between 
June 1989 and May 1991 
Controls: randomly selected 
from local hospitals, singleton 
infants born without a 
reportable congenital anomaly  
- Paternal use of marijuana/hash in the 3-
month period prior to conception was not 
associated with NTDs (crude OR: 0.86, 95% CI: 
0.63, 1.2). 
- Approximately 17% of fathers reported regular 
marijuana/hash use during preconception 
period. 
- Confounder-adjusted estimates not reported; 
authors state adjustment did not meaningfully 
change estimates [32].  
Ewing 1997 Isolated 
membranous 
ventricular 
septal defects 
(IMVSD) 
Face-to-face 
parental 
interview; primary 
respondent was 
generally mother, 
father involved in 
approx. 20% of 
interviews [118] 
Baltimore-
Washington 
Infant 
Study 
(BWIS) 
Cases: Live-born infants with 
confirmed diagnosis of IMVSD 
before 1 year of age (does not 
include fetal deaths). Excluded 
chromosomal defects. 
Controls: Randomly selected 
live-born infants unaffected by 
congenital heart defects. 
 - Paternal use of marijuana in the 6-month 
period prior to conception was associated with 
increased risk of IMVSD (adjusted OR: 1.36, 95% 
CI: 1.05, 1.76). 
- Approximately 16% of fathers reported 
marijuana use during preconception period [30] 
Wilson  1998 Congenital 
heart defects 
(CHDs) 
Face-to-face 
parental 
interview; primary 
respondent was 
generally mother, 
but father 
participated in 
approx. 20% of 
interviews [31].  
Baltimore-
Washington 
Infant 
Study 
(BWIS) 
Cases: Live-born infants with 
confirmed diagnosis of CHDs 
before 1 year of age (does not 
include fetal deaths). Excluded 
chromosomal defects.  
Controls: Randomly selected 
live-born infants unaffected by 
congenital heart defects. 
- Authors investigate paternal risk factors for 8 
subtypes of CHDs, but only report associations 
for paternal marijuana use and two specific 
CHDs: 
    - Transposition of great arteries with intact 
ventricular septum: RR =1.7; AF=12.1 (95% CI: 
8.5, 15.8) 
    - IMVSID: RR =1.4; AF=6.0 (95% CI: 2.2, 9.7) 
- Approximately 25% and 22% case fathers 
reported marijuana use, respectively. 
 
*OR = odds ratio; RR = risk ratio; CI = confidence interval. 
*Wilson et al. did not report confidence intervals for their risk ratios.  
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Shaw et al. was the first study published on paternal cannabis use in relation to any birth 
defect. Authors focused specifically on neural tube defects (NTDs), due to the unknown etiology 
of this defect. They used a case-control study design with data from the California Birth Defects 
Monitoring Program, a state-level active surveillance program. Medical records were reviewed 
for infants delivered at hospitals in elected California counties between June 1989 and May 
1991. Fetuses diagnosed prenatally with an NTD and electively terminated were eligible to be 
considered a case. This analysis focused on 473 eligible cases and 474 eligible controls. 
Participation rates were comparable for cases and controls (87.8% and 88.2%, respectively). 
Women in this study underwent a two-hour face-to-face interview regarding various exposures 
before and during their pregnancy. During this interview, mothers were also asked about illicit 
drug use by the father of the baby during the 3-month period prior to conception. Notably, 
paternal heroin use appeared to be associated with NTDs (OR: 4.6, 95% CI: 0.92, 30.6), though 
this estimate is imprecise likely due to very few fathers with reported heroin use. For paternal 
marijuana/hash use, authors report a crude OR of 0.85 (95% CI: 0.63, 1.2). The effect estimate is 
slightly below the null, but the estimate is somewhat imprecise and includes the null. Authors 
acknowledged that maternal report of this paternal exposure is subject to potential measurement 
error, but did not conduct a bias analysis to see how that measurement error would affect effect 
estimates [32].  
Ewing et al. 1997 and Wilson et al. 1998 both use data from the Baltimore-Washington 
Infant Study (BWIS). However, they focus on different subtypes of cardiac heart defects 
(CHDs), and use different methodological approaches for estimating the association. Case data 
from BWIS come from five pediatric cardiology centers in the Maryland/Washington DC area 
that permit enrollment of infants as soon as they are diagnosed with a CHD.). A strength of the 
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BWIS study is that a cardiologist reviewed participants’ medical records to determine specific 
CHD diagnoses. Exposure was ascertained from a face-to-face parental interview, which may 
increase social desirability bias and result in under-ascertainment of exposure. Wilson et al. note 
that the mother was usually the primary responder, and the father self-reported exposures on 
approximately 20% of the interviews [31]. Ewing et al. do not report how often the father self-
reported exposure (versus the mother reporting about the father), but we assume that the rates are 
comparable to the Wilson paper, since they use the same parent study. While father self-reported 
exposure is presumably more accurate that maternal report, both are imperfect measures that 
could result in under-ascertainment of exposure.  
Ewing et al. 1997 focus on isolated membranous ventricular septal defects (IMVSD), 
which are the most common type of CHDs in the US [30]. Authors suggest that prior studies on 
paternal age and CHDs influenced their decision to study paternal risk factors for IMVSD. 
Paternal cannabis use was defined as any use of marijuana in the 6-month period prior to 
conception. The adjusted association was OR = 1.36 (95% CI: 1.05, 1.76), and was adjusted for 
paternal cocaine, maternal age, maternal cocaine use, sex of infant, and race/ethnicity; however, 
not adjusted for other potentially important confounders, such as other paternal drug use, 
maternal nutritional factors, and SES. Authors found that paternal age did not meaningfully 
modify the effect (though it was a strong modifier for the paternal cocaine-IMVSD association).  
Unlike the other two papers, Wilson et al. was not a typical exposure-outcome analysis. 
Instead, authors aimed to estimate attributable fractions for various risk factors for cardiac 
malformations (another term for CHDs). The authors’ rationale was that attributable fractions 
can directly inform how effective various interventions would be in reducing absolute numbers 
of CHD cases. Because attributable fractions assume causality, authors limited their analysis to 
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exposures they with “potentially causal effects” on CHDs. The analysis focused on eight 
subtypes of CHDs that were clinical confirmed by a cardiologist in the first year of life. 
However, they only report estimates for paternal cannabis use for two of the subtypes, 
assumingly because paternal cannabis did not have a sufficiently large attributable fraction for 
the other subtypes. The relative risk for paternal marijuana use and risk of Transposition of great 
arteries with intact ventricular septum was 1.7 (no confidence interval provided). The relative 
risk of paternal marijuana use and risk of Isolated/simplex membranous ventricular septal defects 
was 1.4 (no confidence interval provided). Among the associations considered, the largest 
attribute fraction was for paternal use of marijuana and transposition of great arteries with intact 
ventricular septum (AF=30.2, 95% CI: 24.2, 36.1). Authors suggest the potential for exposure 
misclassification to impact results may be minimal given the case control differences persisted 
when using “affects controls”. Authors noted their results were consistent with animal models of 
male-mediated teratogenicity, concluding that paternal marijuana use is a plausible risk factor for 
these specific subtypes of CHDs [31]. 
In summary, the epidemiologic literature on paternal cannabis use and risk of birth 
defects is extremely sparse. The three studies described above (see Table 2.2) were from the 
1990s. All three studies used case-control designs, as is common in birth defects research. Shaw 
et al. used surveillance data from California, and the other two studies used data from the 
Baltimore-Washington Infant Study, so the current literature is derived from only two study 
population. Shaw et al. found a null association between paternal cannabis use and neural tube 
defects (NTDs), while Ewing et al. and Wilson et al. found that paternal cannabis use was 
associated with increased risk of specific subtypes of CHDs. 
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2.2.5 Exposure misclassification  
A major challenge of this literature is ensuring accurate exposure measurement of 
cannabis use. Ideally, the most accurate exposure measurement would be a biomarker for 
cannabis use (hair or urine) taken multiple times during the critical window of exposure – in this 
case, during the 3-month window prior to conception. Unfortunately, this approach is impossible 
with the retrospective case-control design that is inherent to most studies of rare outcomes. The 
next best option would be real-time paternal self-report of cannabis use during the critical 
window of exposure, which are not always available. Because studying rare events like birth 
defects is most efficient with a case-control design, previous studies used data from maternal 
report of paternal cannabis.  
Exposure measurement error is possible due to (1) mother’s lack of awareness of father’s 
true cannabis use, (2) mother’s inability to recall father’s cannabis use, or (3) mother’s 
discomfort or hesitancy in reporting father’s true cannabis use. Of particular interest is whether 
this exposure misclassification is differential by case status, since differential misclassification is 
more likely to bias the effect estimates. Our proposal will use a computer-assisted maternal 
report of paternal cannabis, acknowledging it is an imperfect but acceptable method of exposure 
ascertainment if we take care to examine and quantify the possible impact of exposure 
misclassification (see Aim 2 Methods).  We aim to conduct a probabilistic bias analysis to 
quantify how potential exposure misclassification could change our effect estimates. Observed 
data and information from the cannabis literature will inform semi-Bayesian priors and 
distributions of sensitivity and specificity. Details of our analytic approach can be found in 
Section 3.2.4. Given the issues with potential exposure misclassification in the literature, we 
hope this rigorous bias analysis will put the results of Aim 2 in appropriate context.
 32 
CHAPTER 3: RESEARCH METHODS 
3.1 Aim 1 Methods  
The goal of Aim 1 is to conduct an age-period-cohort analysis of current (past 30 days) 
cannabis use among men and women of reproductive age from 2002 to 2014 using a nationally-
representative data source. Sub-aims include (1a) estimating risk factors for recent cannabis use, 
(1b) evaluating if period effects differ by gender, and (1c) evaluating time trends in risk 
perception towards regular cannabis use.  
3.1.1 Study design and population 
 The National Survey on Drug Use and Health (NSDUH) is the largest nationally-
representative survey of drug use in the United States. NSDUH uses an annual cross-sectional 
survey design. The survey provides national data on the use of tobacco, alcohol, and illicit drugs. 
In addition to detailed questions on drug use patterns, the survey also covers mental health 
issues, behavioral issues, and attitudes towards drug use. The survey began in 1971 and was 
originally conducted every other year, but demand for current, accurate information on drug use 
in the 1990s prompted the survey to be conducted annually [119]. NSDUH is authorized by 
Section 505 of the Public Health Service Act, which requires regular data collection on the level 
and patterns of substance use [120]. The survey is run by the Substance Abuse and Mental 
Health Services Administration (SAMSHA), an operating division within the US Department of 
Health and Human Services [2]. Since 1988, the operational duties of the survey are conducted 
by Research Triangle Institute (RTI) International [119].  
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 Population: The source population is the civilian, noninstitutionalized US population 
aged 12 years or older from 2002 to 2014. Individuals excluded from the sample are active 
military personnel, residents of institutional group quarters (e.g., prisons, nursing homes, mental 
institutions, long-term hospitals), and homeless persons not living in a shelter at the time of the 
survey (Methods guide). Data collection takes places in all 50 states and Washington DC.  
While the survey has been conducted regularly since 1971, it underwent major changes in 
2002. Specifically, some drug use questions were modified and all participants were offered a 
$30 compensation for participation from 2002 onwards. Since this modification changed the 
quantity and demographics of survey respondents, NSDUH administrators advise against making 
inferences on temporal trends before and after 2002.  Therefore, we focus our analysis on the 
temporal trends from 2002 to 2014, the most recent study year with available data. Moreover, 
this time period captures significant changes in cannabis legality and social norms that are of 
interest in this analysis. 
 Sampling method: A random sample of US households is selected, and a professional 
interviewer from RTI makes a personal visit to each selected household. Specifically, a 
multistage clustered sampling design is used. Briefly, the source population is grouped by 
geographic “clusters”, then simple random samples are taken within these clusters. Each state 
was geographically partitioned into roughly equal-sized regions according to population, called 
state sampling regions (SSRs). The cluster sampling had three stages: (1) census tract, (2) census 
block, then (3) compact clusters within census block. The goal of this sampling division was that 
each area yielded, in expectation, roughly the same number of interviews within each state 
during each quarterly data collection period [119]. All SSRs had samples sizes sufficient to 
support reliable direct estimates, while maintaining efficiency for national estimates [119].   
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Note that the inclusion criteria of “households” also includes non-institutional group 
quarters, e.g. shelters, boarding houses, college dormitories, migratory workers’ camps, and 
halfway houses [2]. Once a household is chosen, no other household can be substituted. After a 
brief screener interview, one or two residents of the household (over 12 years of age) may be 
asked to participate in the survey. Participation is voluntary; participants that complete the 
survey receive $30 in cash. All selected persons are encouraged to participate, whether or not 
they use or know anything about tobacco, alcohol, or drugs [120]. The NSDUH study has a strict 
quarterly schedule to ensure that interviews are conducted equally across the calendar year. The 
final sample size of completed surveys varies by year; the most recent (2016) NSDUH is 
designed to yield 67,500 completed interviews (field guide).  
Data collection: Participants complete the survey in the privacy of their own home. The 
trained RTI interviewer sets up the computer-assisted interview on a touch-screen Samsung 
Galaxy tablet, and the participant completes the entire survey on the tablet. The interview is 
trained to step away and not view the computer, so the participants’ responses remain 
confidential. No prior computer skills are necessary to complete the survey, and the trained 
interview sets up the tablet in such a way that the participant need not worry about the technical 
aspects of the computer-assisted interview. Small portions of the interview are conducted via 
computer-assisted personal interviewing (CAPI), where the interviewer asks the questions and 
records the answers on the tablet. Sensitive questions, including questions on cannabis use, are 
completed using audio computer-assisted self-interviewing (ACASI), where the respondent 
listens to the questions and enters his/her own response [119]. The ACASI approach ensures that 
the interviewer is unaware of the respondent’s answers. On average, the survey takes about an   
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hour to complete [120]. Interviewers undergo rigorous training and have a detailed “Interviewer 
Field Guide” to guide them through ambiguous situations during data collection. Figure 2.6 is a 
flowchart that details the data collections steps for NSDUH.  
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Figure 3.1. Flowchart of NSDUH screener and interview process  
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Confidentiality of data: Full names are never recorded or associated with a participant’s 
answers, and participants are informed about this anonymity prior to completing the survey. The 
confidentiality of the answers provided are actually protected under federal law by the 
Confidential Information Protection and Statistical Efficiency Act of 2002 (CIPSEA), so by law, 
all responses can only be used for research purposes. Each survey data file is identified only by a 
code number, and is electronically submitted to RTI the same day the survey is completed [120].  
3.1.2 Exposure Assessment 
The exposure – any cannabis use in past 30 days – is ascertained from the NSDUH 
survey. Specifically, the cannabis interview questions are asked using audio computer-assisted 
self-interviewing (ACASI), where the respondent listens to the questions and enters his/her own 
response (described in Section 3.1.1). This method is advantageous, as compared to exposure 
assessment methods from previous APC analyses, since the question is not asked face-to-face by 
an interviewer, therefore reducing stigma and potential misreporting.  
The NSDUH survey contains multiple questions regarding cannabis use. The cannabis 
section of the survey opens up with a brief definition of cannabis, and re-emphasized that this 
information is for research purposes only and will be kept confidential. See Figure 3.2 for the 
exact wording of the survey’s introduction to cannabis.  
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Figure 3.2. NSDUH 2014 survey introduction to cannabis questions 
 
Then, the survey asks a handful of questions about ever/never use, age at first use, and 
frequency of use. For this analysis, we focus on any cannabis use in the past 30 days, which is 
derived directly from the question labeled ‘MJLAST3’. See Figure 3.2 for the exact wording of 
this specific cannabis use question. Note that the question asks about ‘time since last use’, and 
the survey repeats this question up to three times. For example, if a participant responded ‘don’t 
know or refuse’ to the first question, the question pops up again on the screen asking for their 
‘best guess of time since last use’. If the participant again responded ‘don’t know or refuse’, then 
the question pops up a third time, acknowledging that this information is personal and reminding 
the participant that the information is kept confidential (see Figure 3.3). This repeated-question 
method ensures that respondents who initially respond ‘don’t know or refuse’ are given ample 
opportunities to report their true cannabis use. 
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Figure 3.3. NSDUH 2014 survey questions about time since last cannabis use 
 
 The exposure will be coded as a binary variable (yes/no use in last 30 days). If 
participants click response ‘1’ for MJLAST3, then they are coded as ‘yes’. If participants click 
‘2’, ‘3’, or reported never using cannabis in question MJO1, then they are coded as ‘no’. If 
participants changed their response on questions ‘MJRECDK’ or ‘MJRECRE’, then the most 
recent response is used (see Figure 3.3). For example, if participant Bob clicks ‘don’t know or 
refuse’ for MJLAST3, but then clicks ‘1’ for ‘MJRECDK’, then he is classified as a ‘yes’. These 
follow-up questions hopefully improve measurement of true exposure by repeating the question 
and remind participants of the confidentiality of their responses. If a participant reports ‘don’t 
know or refuse’ to all three questions, he/she will be excluded from the main analysis. However, 
we will conduct a sensitivity analysis – including all the ‘don’t know or refuse’ as ‘yes’, then 
including them all as ‘no’ – to estimate the bounds of the effect estimates.  
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3.1.3 Age, period, and cohort definitions  
 An age-period-cohort analysis requires specific definitions for age, period, and cohort 
that remain consist across the study period. Here, we briefly specify the exact coding of these 
three variables. In the Core Demographics section of the survey, the survey asks date of birth, 
and automatically calculates current age (see Figure 3.4). This variable will be used to specify 
age and cohort (represented by year of birth). Individuals less than 12 years of age are ineligible 
for the study, so the age variable will be truncated, by design, at age 12. There is no upper age 
limit for participation in the study. The age variable was categorized as follows by NSDUH 
study administrators: integers from age 12-21, two-year categories from 22-25, five-year 
categories from 26-34, and 14-year categories from 35 onwards. These categories best 
represented change in drug use patterns, since habits often fluctuate greatly among teenagers and 
became stable later in life. Therefore, we will categorize age in accordance with the NSDUH cut 
points. Since this aim is focused on populations of reproductive age, age eligibility will be 15-49 
for men and women (based on World Health Organization definitions) [121]. Indicator variables 
in the regression model will indicate each age category; the age group with the lowest cannabis 
use prevalence will serve as the reference group.  
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Figure 3.4. NSDUH 2014 survey questions for age and cohort variables 
 
The exact birthdate is not available in the public-access data, so ‘cohort’ will be 
calculated by subtracting ‘age’ from ‘study year’. For example, if a participant is 14 years old 
when completing the 2014 survey, then cohort will be calculated as: 2014 (study year) – 14 (age) 
= 2000 (cohort). Cohort will then be categorized by decade (e.g. born in the 1970s, born in the 
1980s, etc.). This categorization best represents generational effects while simplifying 
interpretation, and is consistent with previous APC analyses in this literature. Indicator variables 
will be used to represent each cohort; the cohort with the lowest cannabis use prevalence will 
serve as the reference group.  
The period will be represented by the year the survey was administered, and will be 
dichotomize to before and after 2012 (see Section 3.1.4.1 for explanation). Briefly, 
dichotomizing the period effect constrains one of the three parameters, thereby addressing the 
model identification issue. Moreover, we hypothesize that period effects will likely occur in 
2012, since the first states legalized recreational use of marijuana in November 2012. Table 3.3 
depicts the categorization of the age, period, and cohort variables.  
 42 
Table 3.1. List of categories for age, cohort, and period variables for Aim 1 analysis 
Age Cohort Period 
15-17 1930s 2002 
18-21 1940s 2003 
22-23 1950s 2004 
24-25 1960s 2005 
26-29 1970s 2006 
30-34 1980s 2007 
35-49 1990s 2008 
 2000s 2009 
  2010 
  2011 
  2012 
  2013 
  2014 
 
3.1.4 Analysis 
3.1.4.1 Specific Aim 1 – Main analysis  
 The goal of this APC analysis is to quantitatively estimate the independent effects of age, 
period, and cohort on prevalence of past-month cannabis use in the US. We will use nationally-
representative NSDUH data from 2002 to 2014. The measurement and definition of the outcome 
of interest – prevalence of past-month cannabis use – is detailed in sections 3.1.1-3.1.3. All 
analyses for this aim will be conducted in R, specifically ‘base R’ for data management, ‘ggplot’ 
package for graphics, and ‘apc’ package for the age-period-cohort modeling [122].  
 Introduction to APC models: Conceptually, the APC model is a regression model that is 
incorporating age, period, and cohort as predictors of the outcome of interest. The basic linear 
form of this regression model can be written as:  
𝑅𝑖𝑗 = 𝜇 + 𝛼𝑖 +  𝛽𝑗 + 𝛾𝑘 + 𝜀𝑖𝑗 
where R represent the rate of the outcome of interest for the ith age group at the jth time period, μ 
denotes the intercept, alpha denotes the ith row age effect, β denotes the jth row period effect, γ 
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denotes the kth row cohort effect, ε denotes random error. Subscript i refers to the age group, 
subscript j refers to the time period, and subscript k refers to the cohort category. [52].  
 In the context of Aim 1, the outcome (𝑅𝑖𝑗) is a binary variable for any cannabis use in the 
past month. This model uses individual-level data for all parameters. The age, period, and cohort 
parameters will be categorical indicator variables. Categories of these three parameters are laid 
out in Table 3.3. Since no covariates predict age, period, or cohort (e.g. no arrow on the DAG 
from covariate to exposure), no confounders need to be included in the model. We will assess 
potential effect-measure modification by gender in Sub-aim 1b (see 3.1.4.2).  
This analysis will be conducted using the ‘apc’ package in R, an open-source tool created 
by Bent Nielsen at Oxford University [122]. The analysis will follow statistical guidelines laid 
out in the ‘Age-Period-Cohort Models: New Models, Methods, and Empirical Applications’ 
book by Yang Claire Yang and Kenneth C. Land [52].  
 Model identification problem: A major issue in APC analysis is the model identification 
problem. Briefly, a key assumption in the APC data structure is that this linear relationship holds 
true: “Period – Age = Cohort.” Because of this perfect linear relationship, a unique solution to 
the ordinary least squares (OLS) estimator does not exist in the linear APC regression model. In 
other words, there are an infinite number of possible solutions of the matric equation, so it is not 
possible to estimate the effect of age, period, and cohort separately without imposing at least one 
constraint on the coefficients [52]. In the current literature, there are a few different solutions to 
the model identification problem. We plan to use unequal categorization of age, period, and 
cohort indicators to ‘break’ the algebraic linearity between the three variables and therefore solve 
the model identification problem [52]. Specifically, age will be categorized in unequal categories 
available in NSDUH public-access data, cohort will be categorized in 10-year periods to capture 
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generational effects by decade, and period effects will be categorized in 1-year categories since 
period effects are more susceptible to short-term changes in social norms and policies. See Table 
3.1 for details on parameter categorization.  
3.1.4.2 Specific Aim 1a – Correlates of current cannabis use 
 The demographic make-up of the cannabis user population has changed over time, and 
varies by study population (see Section 2.1.2). Moreover, previous descriptive epidemiology on 
the cannabis user population mostly focused on past-year use. To characterize the current (past 
month) cannabis user population, we will report the distribution of key covariates among users 
and non-users in the NSDUH population. Distribution of covariates will be reported for the 
overall study population, then stratified by period (before and after 2012), to qualitatively assess 
demographic changes in the user population. Additionally, we will use a logistic regression 
model to assess how covariates are associated with odds of past-month cannabis use, both crude 
and adjusted. Covariates of interest include: age, gender, race/ethnicity, educational attainment, 
urbanity, age at first cannabis use, cigarette smoker status, alcohol use, use of hard drugs (i.e. 
heroin, cocaine, methamphetamines, etc.), and risk perception towards regular cannabis use. 
Covariate data will come from the NSDUH survey; results will be presented in a Table 3.1 
format.   
3.1.4.3 Specific Aim 1b – Age, period, cohort effects 
We plan to estimate age, period, and cohort effects from a fully-specified model as 
detailed in section 3.1.4.1 (main analysis of Aim 2).   
3.1.4.4 Specific Aim 1c – Stratified by gender 
Cannabis use frequency differs by gender; US men are more likely than US women to 
report past-year cannabis use [2]. National trends of cannabis use also appear to differ by gender, 
with trends for women increasing while trends for men remain stable in the past decade [2]. 
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Moreover, women’s risk perception of cannabis use is declining faster than men’s in the past 
decade [10]. Due to these gender difference in cannabis use and trends of use of time, we aim to 
qualitatively compare if age, period, and cohort effects differ by gender – with a particular 
interest in the period effect. To achieve this aim, we will stratify the APC analysis by self-
reported gender. In our results section, we plan to present model results for the overall study 
population, then results stratified by gender. No statistical tests will be conducted to test 
differences by gender.  
3.1.5 Power calculations  
 Since the APC analysis is not a hypothesis test, traditional power calculations do not 
apply. However, we do want to ensure that we have sufficient data to validly parse out the age, 
period, and cohort effects of cannabis use.  
 Figure 3.5 depicts the distribution of cannabis use across the study period (2002-2014). 
The number of past-month users for each study year ranges from 5272 to 6336; no study year has 
less than 5000 past-month users. Therefore, we should have sufficient exposed samples for each 
study year. Table 3.4 depicts the age distribution by study year in the NSDUH population, 
showing sufficient sample size for the age by period comparisons. Note that the cohort variable 
is still being created; once this is complete, we will assess age by cohort by period cross-
tabulations to ensure sufficient sample size in all cells. 
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Figure 3.5. Bar plot of cannabis use distribution by study year 
 
Table 3.2. Age distribution of NSDUH population by study year 
 AGE 15 16 17 18 19 20 21 22-
23 
24-
25 
26-
29 
30-
34 
35-49 50-
64 
STUDY 
YEAR 
             
2002 2844 2776 2774 2397 2329 2177 2253 4378 4194 2396 3134 8306 2787 
2003 3060 3011 3015 2630 2280 2302 2292 4511 4368 2434 3128 8096 3052 
2004 3116 3010 2969 2686 2370 2255 2277 4545 4342 2609 3101 8052 3072 
2005 3232 3209 3047 2563 2387 2296 2257 4512 4461 2608 2887 8133 3111 
2006 3193 3159 3030 2524 2283 2143 2263 4396 4323 2646 2860 7697 3606 
2007 3079 3124 3032 2603 2383 2256 2260 4426 4389 2810 3017 8213 3298 
2008 3062 3180 3084 2811 2468 2280 2342 4520 4468 2732 2806 7788 3290 
2009 3106 3102 3152 2673 2516 2299 2307 4542 4424 2690 2913 7802 3439 
2010 3117 3188 3208 2638 2460 2388 2380 4629 4580 2783 3106 8313 3506 
2011 3239 3409 3323 2639 2347 2423 2448 4711 4615 2670 2956 7619 4219 
2012 2956 3058 3038 2469 2223 2271 2354 4707 4591 2628 2864 7391 3923 
2013 3006 3058 2983 2343 2122 2244 2220 4643 4570 2557 2889 7511 3936 
2014 2344 2356 2217 1664 1543 1639 1611 3526 3356 3789 4601 11235 5361 
 
3.1.6 Addressing gaps in literature 
Broadly, there are three main limitations of this literature. First, there is a lack of APC 
analyses with data from 2000 onwards, which is a major gap in the literature in light of the 
rapidly changing socio-cultural norms, laws, and use patterns of cannabis. Meich et al. did 
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include data up until 2009, and the overall time trends, cohort effects, and period effects were 
substantially different as compared to previous APC analyses on the same outcome variable. 
This suggests that the landscape of APC effects and overall time trends in cannabis use are 
changing in recent years. We plan to address this gap by including data up until 2014. This 
would be the most up-to-date APC analysis, and would include five additional years of data as 
compared to the Meich et al. analysis. Moreover, these five additional years (2010-2014) reflect 
major changes in cannabis policy 28 states have medically or recreationally legalized cannabis in 
this time period, so it is crucial to understand how patterns of use are changing in response to 
these policy shifts [11].  
Second, two out of the four studies do not have comparable study populations. Piontek et 
al. is focused in German adults. While results of this analysis are interesting, the socio-cultural 
norms surround cannabis use are likely very different between German and U.S. populations. 
Moreover, period effects are very different in the two settings, since the U.S. has rapidly 
changing laws about medical and recreational cannabis, whereas Germany’s cannabis laws have 
remained fairly steady over the past few decades. Therefore, the Piontek et al. analysis does not 
translate to our population of interest. Johnson et al. conducted their APC analysis on age at first 
marijuana use, which is a very different variable than marijuana use prevalence. Given that many 
individuals try cannabis once or twice in their youth but do not continue to use, age at first use is 
probably not a strong indicator of current cannabis use. Therefore, the Johnson et al. analysis 
does not translate to our study question.  
Third, most APC analyses on cannabis use prevalence focus on ever/never use in the past 
12 months. This measure, while useful in some contexts, does not represent “recent” or “current” 
cannabis use. As mentioned by Piontek et al, ever/never use in past 12 months lumps together 
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occasional users and regular users, and therefore might not be a sensitive outcome definition for 
changing use trends. Additionally, we are interested specifically in cannabis use among men and 
women of reproductive age, due to the potential adverse effects on reproductive health. Though 
evidence is limited, the adverse effects on reproductive health appear to be due to recent (i.e. past 
three months or sooner) use. As detailed in Section 2.2.1, cannabis use in the past three months 
can adversely affect sperm quality. The three-month window is biologically relevant, since 
spermatogenesis takes approximately three months. The window of exposure for women is less 
clear, though a few preliminary studies (detailed in Section 2.2.1) suggest that past month 
cannabis use can affect menstruation. Due to our focus on reproductive health, and the need for a 
more specific measure of recent cannabis use, we plan to conduct our APC analysis on past-
month (defined as past 30 days) cannabis use. To our knowledge, this would be the first study to 
examine APC effects of current cannabis use.  
3.2 Aim 2 methods  
The goal of Aim 2 is to estimate the association between paternal 3-month preconception 
cannabis use and prevalence of major birth defects. Sub-aims include (2a) estimating prevalence 
of cannabis use among men in preconception period, (2b) evaluating effect-measure modification 
by paternal age, and (2c) evaluating potential bias due to exposure misclassification.  
3.2.1 Study design and population 
The National Birth Defects and Prevention Study (NBDPS) is the largest and most 
comprehensive population-based case-control study of birth defects in the United States [123]. 
NBDPS has ten study centers located in geographically diverse parts of country (Arkansas, 
California, Georgia, Iowa, Massachusetts, North Carolina, New Jersey, New York, Texas, and 
Utah). Some study centers capture cases and controls from the entire state, while others focus on 
select geographic districts that are representative of the state’s population (see Figure 3.6). 
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During the study period of 1997-2011, approximately 6 million births occurred in the NBDPS 
catchment area. All birth defects cases are identified through state birth defects surveillance 
registries; controls are randomly selected from the source population using birth certificates. 
NBDPS has a total of approximately 44,000 participants. Specifically, a total of 32,187 case-
mothers and 11,814 control-mothers participated in the study. The study design used a 3:1 case-
to-control ratio to ensure sufficient data of a wide variety of birth defects [123]. Because the 
etiology of birth defects is likely heterogeneous, and specific birth defects are rare, it is essential 
to have an extremely large study to have sufficient power to study etiology of specific birth 
defects. Moreover, the case-control design is the most cost-effective approach for rare outcomes 
like specific birth defects [123].  
The source population of this case-control study is all babies born during the study 
period (1997-2011) in selected counties of Arkansas, California, Georgia, Iowa, 
Massachusetts, North Carolina, New Jersey, New York, Texas, and Utah. Specifically, study 
eligibility started with pregnancies ending on or after October 1, 1997, and concluded with 
pregnancies with estimated dates of delivery (EDD) on or before December 31, 2011. A woman 
was ineligible to participate in the NBDPS if she already participated in the study with a previous 
pregnancy, could not complete the interview in English or Spanish, was incarcerated, or did not 
have legal custody of the infant. For three out of the ten centers, women under 18 years at the 
end of her pregnancy were ineligible [123]. Figure 3.6 below shows the catchment area for select 
NBDPS study sites, along with the approximate annual birth population of the catchment areas.  
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Figure 3.6. Overview of NBDPS catchment area for select study sites [101] 
 
3.2.2 Outcome ascertainment 
The case and control selection process was consistent across study site. A broad overview 
of the case and control selection processes are laid out in Figure 3.7.  
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Figure 3.7. Flowchart of NBDPS case and control selection process 
 
Case ascertainment: All potential cases underwent rigorous evaluation by a clinical 
geneticist experienced with birth defects to ensure accurate classification of all birth defect cases. 
NBDPS specifically focused on twenty-four types of structural birth defect that currently have 
unknown etiologies 21 (see Figure 3.8). A unique feature of NBDPS is that many centers 
included stillbirths and induced abortions in the case group, in addition to live births. This 
detailed outcome data addresses issues related to conditioning on live birth, which is problematic 
in other birth defects studies (see Section 3.2.6). Moreover, since all cases are ascertained 
 52 
through active state-level surveillance, potential for missing cases or systematic error in case 
selection are minimized. 
Clinical verification of all cases: 
After cases are identified from each state’s 
Birth Defects Surveillance program, cases 
undergo a rigorous verification process by 
clinical geneticists with expertise in birth 
defects phenotyping. Some birth defect 
phenotypes were classified by the same 
clinical geneticist for all cases for the 
entire study period. For other defect types 
that were more complex to diagnose, 
classification was completed by more than 
one geneticists. The NBDPS clinical 
geneticists developed guidelines that 
detailed the (1) inclusion and exclusion 
criteria for each defect eligible for the 
NBDPS; (2) rationale for including certain 
diagnostic codes for defects and related defects; (3) instructions and rationale for designating the 
final case classification (isolated, multiple, complex); and (4) instructions and recommendations 
to analysts on how the defect type could be analyzed in epidemiologic studies. All these 
guidelines were consistent across study site to ensure that the classification process did not differ 
Figure 3.8. List of eligible NBDPS birth defects 
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geographically or by clinical geneticist. Figure 3.8 depicts a broad overview of the NBDPS case 
identification process and where clinical verification of cases fits in this process.  
Specific phenotypes for analysis: Birth defect phenotypes are clinically and etiologically 
heterogeneous. Therefore, specific phenotypes should be analyzed separately when estimating 
causal effects. Various to approaches exist for deciding which phenotypes to focus on to best 
address Aim 2. Traditionally, we would rely in current literature to inform specific hypotheses 
for which birth defects might be associated with paternal cannabis use. However, this literature is 
too limited for meaningful inference. Another approach would rely on the proposal biological 
mechanism of preconception cannabis use on fetal development. As described in section 2.2.1, 
cannabis affects sperm quality by binding cannabinoid receptors, but how this mechanism affects 
specific birth defects differently is unknown.  
Therefore, we focus broadly on the most prevalent birth defect phenotypes NBDPS, 
which reflect conditions arguably significant to public health. Specifically, we focus on NBDPS 
defects with at least 500 isolated cases during the 1997-2011 study period. Since no strong 
rationale exists for focusing on specific birth defect phenotypes, we take a more exploratory 
approach: we are interested if paternal cannabis has an effect any of the most common birth 
defect phenotypes. This approach best suits the nature of the current literature, research question, 
and public interest. Moreover, this approach ensures sufficient power to investigate this 
relationship between a relatively rare exposure and quite rare outcome. Defects included in our 
analysis are outlined in Table 3.3, alongside the number of cases available in NBDPS (1997-
2011). While we focus on the most prevalent defects in NBPDS, we include Table 3.4 as a 
reference to show that the seven most prevalent birth defect phenotypes in the US and consistent 
with the defects included in our analysis. Data in Table 3.4 are aggregated from state-specific 
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active and passive surveillance systems from 2008-2012 and are weighted to be nationally 
representative [89]. 
Table 3.3. Selected birth defect phenotypes for Aim 2 (N) 
Birth defect phenotype Total cases Isolated cases Multiple cases 
Anencephaly and craniorachischisis 662 592 70 
Spina bifida 1297 1140 154 
Cleft palate 1631 1310 321 
Cleft lip with cleft palate 2052 1748 304 
Cleft lip without cleft palate 1109 1031 78 
Hypospadias second/third degree 2607 2328 278 
Transverse limb deficiency 732 613 118 
Craniosynostosis 1627 1472 154 
Diaphragmatic hernia 883 673 200 
Gastroschisis 1450 1315 135 
DTransposition of the great arteries 
(Level 2 Code) 781 579 43 
Hypoplastic left heart syndrome (Level 2 
Code) 669 594 59 
RVOT defects - restricted (Level 3 and 
Level 2 Codes) 2149 1422 97 
RVOT defects - excluding Ebstein cases 
(Level 3 and Level 2 and Level 1 Codes) 1998 1310 87 
Pulmonary valve stenosis (Level 2 Code) 1591 1071 62 
VSD perimembranous (Level 2 Code) 1700 916 128 
VSD muscular (Level 2 Code) 685 . . 
ASD secundum (Level 2 Code) 2508 1260 285 
*Congenital heart defect sample sizes reflect ‘simple’ and not ‘associated’ defects 
Table 3.4. Most prevalent major structural birth defect phenotypes in the US, 2008-2012 [67] 
Birth defect phenotype Estimated # of cases  per 10,000 live births 
(1) Hypospadias 64.7 (23.0, 106.3)  (among male live births) 
(2) Atrial septal defects (ASD) 64.7 (0, 171.7) 
(3) Ventricular septal defect (VSD) 43.4 (10.1, 76.6) 
(4) Pulmonary valve atresia and stenosis 8.3 (0.5, 16.2)  
(5) Cleft palate alone 6.1 (2.2, 10.0)  
(6) Cleft lip w/ cleft palate 5.9 (2.1, 9.6) 
(7) Coarction of the aorta 5.6 (0, 14.2) 
*Excludes chromosomol defects 
*Estimated among live births only  
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Due to potential etiologic heterogeneity, we will estimate the effect of paternal cannabis 
use on each specific phenotype. For example, we will separately estimate the effect of paternal 
cannabis on gastroschisis and hypospadias. The analysis will be conduct on ‘isolated’ defects for 
non-heart defects and ‘simple isolated for heart defects. Power calculations for these specific 
phenotypes are presented in section 3.2.5. Table 3.3 summarizes the broader birth defect 
groupings and specific phenotypes within each grouping. 
Control ascertainment: NBDPS has population-based control selection. Controls were 
randomly selected from the source population that represents the geographic region and time 
period of the cases. Specifically, they are simple random sample of the birth certificates of the 
source population, and are contacted for participation in the same way as cases (e.g. by mail and 
phone). All controls are reviewed by the clinical geneticist; infants that have a major birth 
defects are excluded from the control group. Note that potential controls that are later found to 
have a birth defect do not move to the case group; they are removed entirely from the study 
population. Address information for all cases and controls were reviewed by study staff to ensure 
residence in the catchment area during the pregnancy. The monthly number of controls selected 
was proportional to the number of births in the same month in the previous year to minimize 
seasonal effects on control sampling. This rigorous population-based control sampling reduces 
potential selection bias by ensuring that control accurately represent the source population. 
3.2.3 Exposure assessment 
Interview: Trained interviewers conducted a one-hour computer-assisted telephone 
interview (CATI) with each mother in the study. Interviewers guided participants through the 
questions, while participants entered information into the online questionnaire. These interviews 
were scheduled at the mother’s convenience, offered in both English and Spanish, and 
sometimes completed over the course of multiple telephone calls. The CATI asked detailed 
 56 
questions regarding diet, drug use, demographics, lifestyle factors, occupation, environmental 
exposures, pregnancy history, fertility treatments, medical conditions, and psychological 
conditions during both the preconception and pregnancy periods. The CATI also asks the mother 
about the father of the baby, notably about his drug use during the periconceptional period.  
Exposure definition: The exposure of interest - preconception paternal cannabis use - 
will be defined as ever/never use of marijuana during the 3-month preconception period. 
This will be derived from maternal report of paternal cannabis use from the CATI, explained 
above. At one point during the study period, the CATI underwent some slight changes. The 
CATI version used during the first part of the study period will be referred to as the classic 
CATI, and the version used during the latter part of the study period will be referred to as the new 
CATI. The classic and new CATI ask about paternal cannabis use slightly differently.  
The classic CATI was administered approximately to 1997-2005 EDDs, and it asks about 
marijuana and hash use from 3-months preconception to date of infant birth. Specifically, 
question G1 asks “Between (-3) and (DOIB), did (NOIB)’s father use any of the following 
recreational or street drugs?” and asks separately about ‘marijuana’ and ‘hash’ (see Figure 3.9). 
If the response is yes to any of the drugs, the respondent is then asked to specify the exact 
month(s) of use in context of conception, e.g. B3 represent 3-months prior to conception (see 
Figure 3.10). 
The new CATI was administered to 2006-2011 EDDs, and it asks about marijuana and 
hash use from 3-months preconception to time of conception. Specifically, question F17 asks “In 
the 3 months before pregnancy, which would be (B3) through (B1), did ([NOIB]’s/the) father use 
any of the following recreational or street drugs?” then asks about ‘marijuana’ (see Figure 3.11). 
No follow-up questions are asked regarding exact timing of drug use.  
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Figure 3.9. Classic CATI question regarding paternal marijuana use, used for expected delivery 
dates 1997-2005 
 
See Figures 3.9 and 3.10 for the exact wording of the classic CATI questions, and Figure 3.11 
for the exact wording of the new CATI questions.  
 
Figure 3.10. Classic CATI question regarding timing of paternal marijuana use, used for 
expected delivery dates 1997-2005 
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Figure 3.11. New CATI question regarding paternal marijuana use, used for expected delivery 
dates 2006-2011 
 
In summary, there are two main differences in the classic and new CATI questions about 
cannabis use. First, the classic CATI asks about three months prior to conception up until date of 
infant birth, so it includes exposure during the pregnancy time frame, whereas the new CATI 
only asks about the timeframe of interest (three months prior to conception up until time of 
conception). However, the classic CATI includes a follow-up question, specifying when in the 
periconceptional period marijuana was used. To appropriately ascertain exposure during the 
preconception period, we will recode fathers as ‘exposed’ only if the cannabis use occurred 
during the preconception period. In other words, fathers that used cannabis during the pregnancy, 
but not during the 3-month period prior to conception, will be categorized as ‘unexposed’.  
Second, the classic CATI asks about both marijuana use and hash use, whereas the new CATI 
asks about only about marijuana use. For the classic CATI study years (1997-2005), we will 
include ‘hash use’ in the exposed category, since hash has the same psychoactive components as 
marijuana, and the term is often used interchangeability with marijuana. However, we will 
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conduct a sensitivity analysis where we exclude ‘hash’ from the exposed group to see if this 
change in exposure definition meaningfully changes our effect estimates.  
Handling ‘DK’ responses: Note that respondents can respond ‘yes’, ‘no’, or ‘DK’ (don’t 
know) for the questions regarding paternal cannabis use (see Figures 3.10-3.11). The ‘yes’ and 
‘no’ answers clearly will be categorized as ‘exposed’ and ‘unexposed’; how to handle the ‘DK’ 
responses are less clear. The main analysis will be a complete case analysis, where participants 
with missing exposure data are excluded. We will then conduct a few different bias analysis to 
assess how exposure misclassification may impact our results. These bias analyses are laid out in 
detail in Section 3.2.4.3 (Sub-aim 2b – Probabilistic Bias Analysis).  
Covariate ascertainment: The CATI, described above, asked detailed questions 
regarding diet, drug use, demographics, lifestyle factors, occupation, environmental exposures, 
pregnancy history, fertility treatments, medical conditions, and psychological conditions during 
both the preconception and pregnancy periods. The CATI also asks the mother about the father 
of the baby, specifically about his demographics, occupation, and drug use during both the 
preconception and pregnancy period. This extremely detailed questionnaire contains data on all 
known confounders of the paternal cannabis-birth defects association, therefore allowing us to 
control for potential confounding in our analysis (Aim 2). Moreover, the paternal age variable 
from the CATI is essential for investigating potential effect-measure modification by paternal 
age (Aim 2b).  
3.2.4 Analysis 
3.2.4.1 Specific aim 2  
The goal of Aim 2 is to investigate the relationship between paternal self-reported 
preconception cannabis use and major birth defects. Due to the case-control nature of the study 
design, logistic regression will be used to analyze the association between paternal cannabis use 
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(yes/no) and specific birth defect phenotypes (yes/no). The exposure data will come from the 
CATI questionnaire described above (see Section 2.3.3). The outcome data will come from the 
clinically-verified case classifications of birth defects included in the NBDPS data. Since birth 
defects are etiologically heterogeneous, separate logistic models will be run for each birth type 
phenotype group.  
 
Figure 3.12. Directed acyclic graph (DAG) for hypothesized relationship between paternal 
cannabis use and birth defects in offspring 
 
Confounding: All potential confounders will be established a priori using a directed 
acyclic graph (DAG) that will be informed by current literature and NBDPS birth defects 
experts. Figure 3.12 depicts the DAG for Aim 2. A minimally-sufficient adjustment set will be 
identified from this DAG and used in all etiologic analyses. Gestational age at delivery and birth 
weight will not be included in the adjustment set since they are thought to be on the causal 
pathway of the paternal cannabis-birth defects association [124, 125]. Potential confounders 
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include other paternal drug use, paternal cigarette smoking, paternal age, maternal cannabis use, 
other maternal drug use, maternal education, maternal nutritional status, and pregnancy intention.  
Multiple comparisons: We plan to estimate the effect of preconception cannabis use on 
eight birth defect phenotypes (see Table 3.5). Since birth defects are clinically and etiologically 
heterogeneous, these eight phenotypes will be analyzed separately. We will not perform any 
corrections for multiple testing. Corrections for multiple comparisons take a frequentist approach 
to hypothesis testing, assume that the null hypothesis is true, and aims to reduce Type I error. 
However, interpretation of results should not be based solely on hypothesis tests and p-values. 
Instead, inferences should be made on the patterns, magnitude, and precision of results in the 
context of clinical interventions or public health policy [126-128].  
Additionally: while correcting for multiple comparisons reduces likelihood of false 
positives (reduces Type I error), it also increases likelihood of false negatives (increases Type II 
error) [129, 130]. The relative value of false positives and false negatives is context-specific. In 
our context of understanding if a prevalent easily-modifiable exposure affects risk of an adverse 
fetal outcomes, false negatives are – arguably – more harmful for public health than false 
positives. Therefore, we will not perform any corrections for multiple comparisons. Resulting 
manuscript(s) will be clear about the number of tests conducted, so the reader has this knowledge 
when interpreting our results.  
3.2.4.2 Sub-aim 2a – Estimating prevalence of preconception cannabis use 
While the NSDUH study population in Aim 1 can provide nationally-representative 
estimates of cannabis use prevalence among persons of reproductive age, the NBDPS study 
population in Aim 2 is uniquely suited to provide prevalence estimates during the preconception 
period. Therefore, we will report the prevalence of any reported cannabis use during the 
preconception period among control-fathers in the NBDPS study population. We will report the 
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(1) overall prevalence in study population, (2) prevalence stratified by study year (1997-2011), 
and (3) prevalence stratified by state to qualitatively assess geographic and time trends. To our 
knowledge, this will be the first estimate of preconception paternal cannabis use prevalence in 
the 21st century.  
3.2.4.3 Sub-aim 2b – Crude and adjusted results 
We aim to estimate crude and adjusted odds ratios and 95% confidence intervals for the 
association between paternal cannabis use during the preconception period and odds of specific 
birth defect phenotypes, as described in section 3.2.4.1 (Aim 2 main analysis).  
3.2.4.4 Sub-aim 2c – Probabilistic bias analysis  
The exposure in this study is susceptible to misclassification for two main reasons. First, 
cannabis is a sensitive exposure to ask about, and participants may have various reasons for 
misreporting their cannabis use. For example, they may not want to admit to using an illegal 
substance to a government-funded research study, or they think that cannabis use is “socially 
undesirable” and therefore feel uncomfortable reporting it. Second, the exposure data is derived 
from maternal report, and mothers may not know the true level of paternal exposure. Of 
particular interest is whether this exposure misclassification is differential by case status, since 
differential misclassification is more likely to bias the effect estimates. It is possible that the first 
mechanism of misclassification is differential by case status (i.e. variations of recall bias), but it 
is less likely that the second mechanism of misclassification is differential by case status. We 
plan to address this exposure misclassification in by conducting probabilistic bias analyses with 
various assumption. 
Specifically, we will use a semi-Bayesian probabilistic sensitivity analysis to minimize 
misclassification of the paternal self-reported cannabis use variable. Briefly, this method uses 
different assumptions about the sensitivity and specificity of the observed exposure to get closer 
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to “true” exposure values [131]. For example, we assume perfect specificity (those who report 
‘yes’ to cannabis use are truly exposed) but imperfect sensitivity (20% of participants who report 
‘no’ are actually exposed) – based on priors from the cannabis literature. Moreover, probabilistic 
bias analyses draws from a sample distribution of sensitivity and specificity values, rather than 
assigning fixed values for sensitivity and specificity. We will define an a priori trapezoidal 
distribution of a reasonable range of values for sensitivity and specificity based on priors from 
previous literature. This approach more adequately incorporates uncertainty of exposure 
misclassification as compared to deterministic approaches.  
We will follow the approach established by Tim Lash and colleagues for conducting a 
probabilistic bias analysis [132-134]. We create our own macro based publicly-available SAS 
macro for probabilistic sensitivity analysis called ‘sensmac’, developed by Lash and colleagues 
[134]. This macro simulates the data that would have been observed had the misclassified 
variable been correctly classified given the sensitivity and specific of classification [134]. Using 
this macro, we will simulate two scenarios: (1) non-differential misclassification, where the 
sensitivity and specificity of exposure misclassification is the same cases and controls, and (2) 
non-differential misclassification, where the sensitivity and specificity of exposure 
misclassification differs by case status. 
While this approach makes assumptions of specificity and sensitivity that cannot be 
validated within our data, it at least allows us to understand how measurement error with 
informative priors might, or might not, change the results (>10% change-in-estimate). A similar 
approach was used to minimize exposure misclassification in a 2014 study of maternal cannabis 
use and birth defects in the NBDPS population [135]. Results of this bias analysis will indicate 
the magnitude and direction of expected bias, given a range of input assumptions regarding the 
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distribution of exposure misclassification. This bias analysis will ultimately provide meaningful 
interpretation of effect estimates in this analysis in the context of unknown misclassification of 
exposure. 
3.2.5 Addressing gaps in literature 
 The existing epidemiologic literature on paternal cannabis use and birth defects has four 
major limitations. First, the current literature is extremely sparse and outdated. The most recent 
study was published in 1998, so the data is over 20 years old. Cannabis use has changed 
drastically in the past two decades in terms of frequency of use, demographic patterns of use, and 
changing legal and social norms surrounding cannabis use. Moreover, the potency of marijuana 
has become stronger in the past few decades, so cannabis exposure today is at a higher dose as 
compared to when these studies were published [136, 137]. Our study will be using data from 
1997-2011, so the study population and exposure data is much more up-to-date as compared to 
previous studies. 
 Second, the existing studies have only focused on two types of birth defects – NTDs and 
CHDs. No studies have examined the effect of paternal cannabis on any other type of birth 
defect. Birth defects are phenotypically and etiologically heterogeneous, so it is unlikely that 
results about NTDs and CHDs can be generalized to other types of defects. Therefore, we 
urgently need epidemiologic investigation of paternal cannabis and other subtypes of defects. 
Our study plans to investigate the effect of paternal cannabis on the most prevalent birth defect 
phenotypes, as noted in Table 3.2. Specifically, our study includes hypospadias and oral clefts –
adverse and prevalent birth defects which no previous studies of cannabis use have investigated. 
Therefore, our study would greatly expand our knowledge on the association of paternal 
cannabis and a wider range of major structural defects.  
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 Third, the existing studies have imperfect outcome ascertainment. Shaw et al. used an 
active surveillance system, but they lacked clinical verification of cases. This means that the 
healthcare providers at birth determine the birth defects diagnosis, and these diagnoses were not 
reviewed by a clinical geneticist (or other expert), thus opening up this study to potential missing 
data or potential misclassification of outcomes. Ewing et al. and Wilson et al. – both using BWIS 
data – did have clinical verification of their cases by a cardiologist, which is appropriate since 
they focused on CHDs. These two studies also ascertained cases up until age 1, which is 
important especially for CHDs, which are sometimes not detected at time of birth. However, 
both analyses only included live-born infants; in other words, they both condition on live birth. 
This is problematic, since the exposure (cannabis use) could result in pregnancy loss or 
miscarriage that would be missed by only ascertain live-born cases. In other words, the effect 
estimates from these studies have potential to be biased if (1) authors missed fetal deaths 
resulting from the birth defect under study, and (2) some proportion of those fetal deaths was 
caused by the exposure. Since congenital anomalies often result in fetal death, and since paternal 
cannabis use could plausibly affect risk of fetal death, conditioning on live birth introduces 
potential for this live-birth bias [138].  Our study addresses these two limitations by (1) using 
active surveillance and rigorous clinical verification of all cases by a clinical geneticists with 
expertise in birth defects, and (2) including fetal deaths as eligible for the case group. Though the 
fetal death data is limited to deaths after 20 weeks, so there is potential missing data from early 
pregnancy loss, our proposal still improves upon previous studies and increases our ability to 
control any bias due to conditioning on live birth. Our proposal’s approach improves upon the 
measurement error present in previous studies, and aims to provide more accurate outcome data 
necessary to estimate causal effects. 
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 The fourth limitation relates to exposure assessment. All three existing studies conducted 
face-to-face interviews with the mother (and some cases, the father) regarding paternal cannabis 
use. Cannabis use is a sensitive topic, especially since it is federally illegal and carries social 
stigma [139]. When asking participants about cannabis use, it is essential to use methods that 
make the respondent feel safe, comfortable, and anonymous to ensure accurate reporting. Studies 
comparing accuracy of drug reporting across various questionnaire methods found that lack of 
response to sensitive drug questions was higher in face-to-face studies as compared to other 
survey methods [140]. A recent study specifically compared face-to-face interviewing computer-
assisted self-interviewing, and found that the latter method resulting in higher reporting of 
stigmatized behavior [141]. The mechanism behind this difference is the increased feeling of 
anonymity and decreased personal judgment of using a computer-assistant self-interview as 
compared to a face-to-face interview. Our study will address this limitation by using a computer-
assisted self-interview to ascertain the exposure. However, our exposure measurement – 
maternal report of paternal cannabis use – remains imperfect. The ideal measurement would be a 
biomarker measured during the preconception window. Since birth defects are a rare outcome 
usually studied in a case-control design, measuring a biomarker during preconception period 
would be nearly impossible for any study. A superior method would have been paternal self-
report, which is not available in the NBDPS data. Maternal report of paternal cannabis use is a 
sufficient – but not ideal – exposure measurement. To assess if measurement error introduces 
potential bias in our effect estimate, we will conduct a probabilistic bias analysis, as described in 
the Aim 2 analysis plan. 
 In summary, our proposal contributes meaningfully to our understanding of the paternal 
cannabis-birth defects association by (1) providing much more recent data, (2) investigating birth 
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defects phenotypes apart from NTDs and CHDs for the first time, (3) improving validity of 
outcome ascertainment and reducing live-birth bias, and (4) assessing potential bias from 
measurement error.  
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CHAPTER 4: TRENDS IN PAST-MONTH CANNABIS USE AMONG MEN 
AND WOMEN OF REPRODUCTIVE AGE FROM 2002-2014: AN AGE-
PERIOD-COHORT ANALYSIS1 
4.1. Introduction 
Cannabis is the most commonly used illicit drug among men and women of reproductive 
age in the United States (U.S.) [2-4].  The adverse and beneficial health effects of cannabis use 
are widely debated, but recent evidence suggested that cannabis use may have negative effects 
on reproductive and perinatal health [5-7]. 
Animal studies have shown that tetrahydrocannabinol (THC) – the main psychoactive 
component of cannabis – can disrupt regular menstrual cycles, suppress oogenesis, and reduce 
female fertility [60-62].  THC crosses the placenta [68, 142] and can transfer to breast milk, 
though the infant’s level of exposure via breast milk is uncertain [143, 144]. Epidemiologic 
studies have found maternal cannabis use during pregnancy to be associated with fetal growth 
restriction, certain birth defects, and neonatal intensive care admission [6, 15, 16].  Due to this 
growing evidence on the potential effects of cannabis use on reproductive and perinatal health, 
the American College of Obstetricians and Gynecologists recommends counseling pregnant 
women and women considering pregnancy to discontinue cannabis use. [145]  
Less is known about the potential reproductive effects of paternal exposure.  In a recent 
study of Danish men, sperm quality was significantly lower for regular marijuana smokers (more 
than once a week) compared to non-smokers [21]. THC has been shown to reduce sperm 
                                                     
1 This chapter was submitted to Drug Alcohol Dependence on 9 August 2016. 
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concentration and alter sperm motility in humans [5, 20] and to damage DNA packaging during 
spermatogenesis in both human and animal studies [5, 22]. 
Understanding trends in cannabis use among women and men of reproductive age is an 
essential step toward developing health policy, health education, and targeted interventions to 
mitigate potential adverse reproductive and perinatal health effects from cannabis use [7]. The 
prevalence of recent cannabis use (defined as at least one occurrence in the past month) has 
increased among adults aged 18 to 25 from 16% in 2004 to 20% in 2014 [2].  Moreover, attitudes 
among younger cohorts continue to move towards greater acceptance of cannabis, with the 
percentage of teenagers who perceive “great risk from regular use” significantly declining in the 
past decade [9, 10]. Policies on cannabis legality are also rapidly changing. To date, 24 states 
have legalized medical use, and eight states and the District of Columbia have legalized 
recreational use [11].  Disentangling the effects of age, policy period, and cohort is critical to 
understanding changes in cannabis use over time, as these three parameters are inextricably 
correlated over time but may have independent, potentially modifiable effects. Additionally, few 
contemporary studies have investigated gender differences in cannabis trends, despite substantial 
gender differences and social norms regarding use [146, 147]. 
We conducted an age-period-cohort (APC) analysis to estimate the independent effects of 
age, period, and cohort on past-month cannabis use among men and women of reproductive age 
in the U.S. from 2002 to 2014 using nationally-representative surveillance data. We also 
investigated potential differences in cannabis use trends by gender.  
4.2. Material and methods 
4.2.1 Study population 
We analyzed data from the National Survey on Drug Use and Health (NSDUH). 
Conducted by the Department of Health and Human Services since 1972, the NSDUH uses a 
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repeated annual cross-sectional survey design to measure tobacco, alcohol, and illicit drugs use. 
In addition to drug use patterns, the sur vey also covers mental health conditions, behavioral 
disorders, and attitudes towards drug use.  
The survey uses multistage clustered sampling to ascertain a nationally-representative 
sample of U.S. households [119].  Professional interviewers visit selected household to conduct 
the computer-assisted interviews [119].  Monetary compensation for study participation began in 
2002 and resulted in increased participation; thus, we restricted our sample to 2002 onwards.  
We merged publicly-available NSDUH data across survey years 2002 to 2014.  We restricted the 
sample to those ages 15-49 years at time of interview (n=534,679) to represent populations of 
reproductive age [121, 148]. 
4.2.2 Measures 
The cannabis survey questions were asked using audio computer-assisted self-
interviewing (ACASI), during which the respondent listens to pre-recorded questions on 
headphones and enters his/her own response. This survey method has been shown to improve 
response accuracy, since the question is not asked face-to-face by an interviewer, thereby 
reducing perceived stigma and potential misreporting [140, 141]. During this section, the 
respondent were first briefed on different formats and names for cannabis (e.g. marijuana, hash, 
pot, grass, joints) that are considered exchangeable in the survey. Respondents were then asked: 
“How long has it been since you last used marijuana or hash?” with the following possible 
responses: (1) Within past 30 days, (2) More than 30 days ago but within past 12 months, (3) 
More than 12 months ago, or (4) Never used. Our primary outcome of interest for this analysis 
was any cannabis use in the past 30 days; thus, we combined response categories to create a 
dichotomous variable indicating use in the past 30 days vs. use more than 30 days ago or never 
use (referent group for all analyses).  
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Socio-demographic characteristics, tobacco, alcohol, and other illicit drug use were also 
ascertained from the NSDUH survey. Socio-demographic questions were asked by the trained 
interviewer, while more sensitive questions pertaining to substance use were ascertained using 
the ACASI method described above.  
4.2.3 Statistical analysis  
We examined the distribution of socio-demographic characteristics, tobacco, alcohol, and 
other drug use stratified by individual-level past-month cannabis use in our study sample (see 
Table 4.1).  
First we created age-period contingency tables, overall and stratified by gender, for the 
proportion of past-month cannabis use for each age category and study year. Publicly-available 
NSDUH data provided most ages categorically for confidentiality (e.g. 30-34). Therefore, we 
calculated a range of birth years for a given age/study year intersection and used the median birth 
year for a 10-year period to represent each birth cohort. 
We used log-linear multivariable models to estimate adjusted prevalence ratios (aPR) and 
95% confidence intervals (CI) for associations between age, period, and cohort and proportion of 
individuals reporting past-month cannabis use. The conventional age-by-period array of 
aggregate outcomes categorize age and period in equal interval lengths, thereby creating the 
exact linear dependency between the independent variables (period = age + cohort) that leads to 
the model identification problem [52].  However, in our data, cohort was categorized in 10-year 
intervals - conventional in demographic studies of population based data - to represent potential 
generational effects. Age was categorized in unequal intervals based on NSDUH statisticians’ 
recommendations to best represent age-related changes in drug use. Period was categorized in 1-
year intervals to assess potential year-by-year changes in cannabis use, in the context of 
changing legislation during the study period. We therefore used the differential time interval 
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groupings to break the exact linear dependency between the three variables.[52]  To ensure 
results were robust to effect estimate contrast, we additionally used linear models to estimated 
adjusted prevalence differences (aPD) and 95% CIs for age, period, and cohort effects.  
Descriptive models included confidential survey weight and variance estimation stratum 
from the NSDUH to account for sampling, non-response, and variance adjustment. Weighted 
results are meant to be generalizable to the target population of U.S. adults age 15-49. No 
additional covariates were included in the age-period-cohort models, since no potential 
confounders were identified using a directed acyclic graph [149, 150]. This approach is 
consistent with previous age-period-cohort analysis of substance use [12, 13, 151].  No 
interaction terms were included in the model, since cohort effects can be conceptualized as an 
interaction between age and period. In other words, cohort effects capture how age effects vary 
by time period.  Sensitivity analyses were conducted to assess whether results were sensitive to 
different age, period, or cohort parameterization and referent groups.   
Analyses were conducted using R 2.14.0 and SAS 7.3. 
4.3 Results 
4.3.1 Sociodemographic characteristics 
Overall, 9.9% of the study population reported past-month cannabis use. Past-month use 
varied greatly by age, with prevalence as high as 19.7% for 18-21 year olds and as low as 5.4% 
for 35-49 year olds (see Table 4.1). Compared to those reported no cannabis use in the past 
month, past-month users were more likely to be male, unemployed, and unmarried. Past-month 
users did not differ substantially in terms of family income, educational attainment, and overall 
health status. Past-month cannabis use was associated with current cigarette smoking, past-
month binge drinking, and ever-use of cocaine, heroin, LSD, methamphetamines, and non-
medical use of painkillers (see Table 4.1). 
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4.3.2 Trends from 2002-2014 
The overall prevalence of past-month cannabis use increased from 9.2% in 2002 to 
12.3% in 2014. While the absolute prevalence remained higher for males through the study 
period, the overall trend appeared similar for males and females (see Figure 4.1). 
4.3.3 Age, period, cohort effects 
By simultaneously modeling age, period, and cohort effects on proportion of individuals 
reporting past-month cannabis use, we estimated each independent effect while holding the other 
two factors constant. Note that Figures 4.2-4.4 have varying y-axis limits to best depict results. 
Age had considerably stronger effects on proportion of past-month cannabis use than period or 
cohort. The strongest age effects were observed for 18-21 year olds (aPR: 2.91, 95% CI: 2.57, 
3.30) and 22-25 year olds (aPR: 2.28, 95% CI: 2.03, 2.57), compared to 35-49 year olds (see 
Figure 4.2). Cohorts born in the 1970s, 1980s, and 1990s had slightly higher proportions of past-
month use compared to the 1960s birth cohort, with the strongest cohort effect for 1980 (PR: 
1.21, 95% CI: 1.05, 1.39) (see Figure 4.3). We observed a small but consistently increasing 
period effect for study years 2009 to 2014 compared to 2002 (see Figure 4.4). Most confidence 
intervals included the null; however, period effects for 2013 (aPR: 1.08, 95% CI: 1.01, 1.15) and 
2014 (aPR: 1.16, 95% CI: 1.09, 1.24) were more pronounced.  
4.3.4 Gender differences 
Prevalence of past-month cannabis use was higher among males than females for all age 
groups. The difference was most pronounced for 22-25 and 26-29 year olds: prevalence among 
males was nearly two-fold that among females. The overall increasing trend in past-month use 
from 2002 to 2014 was similar across gender. 
Age effects were stronger for females, most notably for the 18-21 age group (aPR for 
females: 3.32, 95%CI: 2.79, 3.96; aPR for males: 2.62, 95% CI: 2.26, 3.03) (see Figure 4.2). 
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Cohort and period effects were overall similar across gender (see Figures 4.3 and 4.4). However, 
significant period effects were observed for study years 2011 through 2014 among males, but 
only for study year 2014 among females.  
When estimating prevalence differences, the same patterns emerged, though gender 
differences in age effects were mitigated (see Supplemental Table 4.1). Sensitivity analyses for 
alternative referent groups did change the magnitude and direction of effect estimates in some 
cases, but the overall trends remained the same (see Supplemental Table 4.2). Sensitivity 
analyses for alternative categorizations for age, period, and cohort parameters did not 
substantively change our results (see Supplemental Table 4.3).  
4.4 Discussion 
4.4.1 Overall 
This was the first study to examine age, period, and cohort effects on cannabis use in the 
United States since the first states legalized recreational use of cannabis in 2012 and the first 
study to explore differences among men and women of reproductive age. This was also the first 
APC study to consider past-month cannabis use, a more sensitive marker for regular cannabis 
use and potentially related health effects [152-154]. 
Cannabis use was prevalent in this study population, with approximately 10% of 
participants reporting past-month use. We observed a meaningful increase in past-month 
cannabis use prevalence from 9.2% in 2002 to 12.3% in 2014, though trends varied by age 
group. The age-specific trends may reflect cannabis use among young adults that continues into 
adulthood, more now than in prior generations, suggesting a shift in the life-course patterns of 
cannabis use. [49, 155].   This potential explanation is consistent with the subtle cohort effect 
observed, since they reflect that trends (e.g., period effects) differ by age (e.g., age effects) [156]. 
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While we found distinct age, period, and cohort effects on past-month cannabis use, age 
was the strongest independent source of variation, especially for the 18-21 and 22-25 age groups, 
which is consistent with current literature on risk factors for cannabis use. Age was a stronger 
correlate of cannabis use prevalence among women when estimating prevalence ratios. However 
these gender differences were mitigated when estimating prevalence differences, likely because 
the baseline prevalence was lower in females, thus resulting in stronger prevalence ratios. We 
therefore conclude that age effects are strong for both men and women, and the magnitude of 
effects are similar by gender.  
A consistent increase in use across periods suggests that time-dependent socio-cultural 
factors may influence past-month cannabis use.  Notably, the overall period effect was strongest 
for study years 2013 and 2014, which reflect the time period immediately after Colorado and 
Washington legalized recreational cannabis use in 2012. 
State-level legalization in 2012 could influence national period effects in past-month 
cannabis use through multiple pathways [157-159].  First, individuals may have increased access 
to cannabis; this would primarily affect individuals living in states with legalization. Second, 
legalization may reduce risk perception and change social norms surrounding acceptance and use 
of cannabis. Significant decreases in the risk perception surrounding cannabis use in US 
populations from 2002 to 2014 have been documented [10]. Drug use patterns are known to be 
strongly influenced by social norms and other group-level processes [158, 160, 161].  Future 
research could assess these potential mediators, and how effects differ for medical versus 
recreational cannabis use [43].  We cannot necessarily infer that state-level legalization caused 
this period effect because we were unable to account for other time-varying factors during this 
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period that may influence cannabis use. Additionally, more time may need to elapse before we 
see the true period effects from state-level legalization [162]. 
Three earlier studies found strong age effects with a peak in young adulthood, consistent 
with our findings [12, 13, 163].  Kerr et. al. reported a decline in past-year cannabis use among 
men, but stable use among women from 1984 to 2000 [163].  More recently, we observed 
distinct patterns by gender, but increased use among both men and women from 2002-2014. 
Consistent with our results, Kerr et al. also found that age effects were stronger for women than 
for men [163].  Miech et al found a distinct period effect in study years 2000-2009 across all 
ages and cohorts [12], speculating trends may have reflected changing social norms and attitudes 
towards cannabis use [12].  Similarly, we observed a distinct increasing period effect, but of 
more consistent magnitude and precision than was observed by Miech et al. This may suggest 
that period effects were already emerging in the US from 2000-2009 but have since become 
stronger in 2002-2014, perhaps due to even stronger social norms or legislation changes.  
Laws and social norms have changed drastically since the last APC study reported on 
trends through 2009 [10, 157, 162].  The most notable change was in 2012 with the first state 
legalization of recreational cannabis use, so it is timely to examine time trends and drivers those 
trends over the past seven years [158]. Our efforts to understand trends among individuals of 
reproductive age are crucial to public health guidelines and planning, especially in light of the 
growing evidence of adverse reproductive health effects of cannabis use. Moreover, we have 
investigated past-month use, which provides a more temporally relevant measure of use with 
regard to reproductive health effects than would be available from previous studies that 
evaluated past-year cannabis use [164-166]. 
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4.4.2 Limitations 
Self-report of cannabis may be under-reported, and the extent of measurement error may 
differ by age and gender. Moreover, our results could be vulnerable to time-varying changes in 
reporting accuracy either by all participants or by participants of specific age groups: if study 
participants in later years are more comfortable reporting true cannabis use, we may mistake 
increased reporting for increases in actual prevalence. These concerns may be mitigated by 
measures taken within the NSDUH data collection protocol to improve the accuracy of self-
report, including: anonymous reporting without face-to-face interactions with the interviewer, 
reminders of anonymity, and a repeated follow-up approach to minimize non-response.  
By restricting to a 13-year period (2002 to 2014), we are ‘capturing’ each birth cohort at 
specific ages. For example, individuals born in 1965 would be captured in our study at ages 37 to 
49, whereas individuals born in the 1990 would be captured at ages 17 to 29. Since cannabis use 
is most prevalent among young adults, we may be missing the heaviest cannabis use for the 1960 
and 1970 birth cohorts. We adjusted for period and age in the cohort effect estimates, which may 
mitigate this issue by providing cohort trends averaged over all period and age groups, but 
generalization of our results beyond this sample is limited.  Longer study periods could help 
corroborate estimates of cohort effects in past-month cannabis use.  
Finally, we were unable to investigate effect-measure modification by state because the 
public-access NSDUH files do not include data on participants’ residence. Many states 
decriminalized possession and legalized medical and/or recreational use of cannabis over the 
study period. Future studies could look at state-specific data to elucidate how period effects 
differ geographically and by type of legislation change.  
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4.5. Conclusions 
Cannabis use is prevalent and increasing among both men and women of reproductive 
age in the United States, with approximately 12% reporting past-month use in 2014. Prevalence 
almost doubled among women aged 26-34 in particular, which reflects women with the highest 
birth rate. Age, period, and cohort each have independent effects on past-month cannabis use, 
with age having the strongest influences. When holding age and cohort constant, small but 
consistent period effects were observed. Most notably, period effects – which arose from time-
dependent socio-cultural factors – were strongest for 2013 and 2014. State-level cannabis 
legalization in 2012 may partly explain these recent national period effects, though recent period 
effects also fit a larger trend of steady increases in cannabis use in the past decade.  
Cannabis use is common among men and women of reproductive age, and is rapidly 
increasing in the age group of women with the highest birth rates. Understanding trends in 
cannabis use among women and men of reproductive age is an essential step toward developing 
health policy, health education, and targeted interventions to mitigate potential adverse 
reproductive health effects from cannabis use. More epidemiologic research is needed to 
understand the risk factors and reproductive health effects of cannabis use.   
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Table 4.1. Study population characteristics by past-month cannabis use 
  Past-month cannabis use (%) 
  No Yes 
Overall  90.1 9.9 
Age   
    15-17 87.8 12.2 
    18-21 80.3 19.7 
    22-25  84.1 15.9 
    26-29  88.8 11.2 
    30-34 91.5 8.5 
    35-49 94.6 5.4 
Gender    
    Female 92.8 7.2 
    Male 87.3 12.7 
Race/ethnicity   
    Non-Hispanic black 88.6 11.4 
    Non-Hispanic white  89.1 10.9 
    Hispanic 93.1 6.9 
    Asian 96.8 3.2 
    More than one race 83.5 16.5 
    Native American/AK native 87.1 12.9 
    Native HI/Pacific Islander 90.6 9.4 
Education   
    17 or younger  87.8 12.2 
    Less than high school 88.0 12.0 
    High school graduate  89.1 10.9 
    Some college 89.2 10.8 
    College graduate  93.8 6.2 
Marital status    
    Married 95.7 4.3 
    Not married 85.6 14.4 
Employed   
    Full-time  91.6 8.4 
    Part-time 87.4 12.6 
    18 or younger  87.8 12.2 
    Unemployed 83.3 16.7 
    Other 90.4 9.6 
Family income   
    < $20,000 86.0 14.0 
    $20,000-$49,999 89.4 10.6 
    $50,000-$74,999 91.5 8.5 
    ≥ $75,000 92.5 7.5 
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  Past-month cannabis use (%) 
  No Yes 
Cigarette smoking status   
    Current 78.2 21.8 
    Former 93.2 6.9 
    Never 97.5 2.5 
Binge drink in past monthb   
    Yes 79.1 20.9 
    No 94.8 5.2 
Chewing tobacco   
    Never 91.4 8.6 
    Ever 82.4 17.6 
Cocaine   
    Never 93.9 6.1 
    Ever 72.5 27.5 
Crack    
    Never 91.2 8.8 
    Ever 65.8 34.2 
Heroin    
    Never 90.6 9.4 
    Ever 63.6 36.4 
Ecstasy    
    Never 92.9 7.1 
    Ever 60.3 39.7 
LSD   
    Never 92.9 7.1 
    Ever 68.7 31.3 
Methamphetamine   
    Never 91.1 8.9 
    Ever 71.2 28.8 
Painkiller (non-medical use)   
    Never 93.9 6.1 
    Ever 73.0 27.0 
Overall health   
    Excellent  92.6 7.4 
    Very good 89.8 10.2 
    Good 88.5 11.5 
    Fair 87.6 12.4 
    Poor 87.6 12.4 
a Frequencies are weighted for NSDUH sampling structure and reflect 
combined NSDUH 2002-2014 data 
b Binge-drinking is defined as 5 or more drinks in one setting 
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Figure 4.6. Trends in past-month cannabis use among men and of reproductive age from 2002-
2014 
 
 
Figure 4.7. Age effects on prevalence of past-month cannabis use 
 82 
 
Figure 4.8. period effects on prevalence of past-month cannabis use 
 
 
Figure 4.9. Cohort effects on prevalence of past-month cannabis use  
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Supplemental Table 4.1. Age, period, and cohort effects on prevalence of past-month cannabis, 
aPD (95% CI)a 
Parameter Category Overall Women Men 
Age 15-17 0.074 (0.061, 0.088) 0.083 (0.070, 0.097) 0.063 (0.042, 0.083) 
 18-21 0.138 (0.126, 0.150) 0.120 (0.108, 0.132) 0.155 (0.136, 0.174) 
 22-25 0.095 (0.084, 0.106) 0.075 (0.064, 0.086) 0.118 (0.101, 0.135) 
 26-29 0.053 (0.043, 0.062) 0.040 (0.030, 0.049) 0.068 (0.053, 0.083) 
 30-34 0.030 (0.021, 0.039) 0.023 (0.014, 0.032) 0.039 (0.026, 0.053) 
  35-49 REF REF REF 
Period 2002 REF REF REF 
 2003 0.000 (-0.007, 0.007) -0.005 (-0.012, 0.002) 0.004 (-0.007, 0.014) 
 2004 -0.007 (-0.013, 0.000) -0.007 (-0.014, 0.000) -0.005 (-0.016, 0.005) 
 2005 -0.009 (-0.016, -0.002) -0.008 (-0.015, -0.001) -0.009 (-0.020, 0.001) 
 2006 -0.009 (-0.015, -0.002) -0.012 (-0.019, -0.005) -0.006 (-0.017, 0.005) 
 2007 -0.009 (-0.016, -0.002) -0.015 (-0.022, -0.007) -0.004 (-0.015, 0.007) 
 2008 -0.007 (-0.014, 0.000) -0.009 (-0.017, -0.002) -0.005 (-0.016, 0.006) 
 2009 0.003 (-0.004, 0.011) 0.002 (-0.006, 0.009) 0.005 (-0.006, 0.016) 
 2010 0.007 (0.000, 0.014) 0.002 (-0.005, 0.009) 0.012 (0.001, 0.023) 
 2011 0.008 (0.000, 0.015) 0.000 (-0.008, 0.008) 0.016 (0.004, 0.027) 
 2012 0.012 (0.003, 0.020) 0.005 (-0.004, 0.013) 0.020 (0.007, 0.032) 
 2013 0.015 (0.007, 0.023) 0.012 (0.003, 0.020) 0.020 (0.007, 0.033) 
  2014 0.026 (0.017, 0.034) 0.020 (0.011, 0.029) 0.032 (0.019, 0.046) 
Cohort 1960 REF REF REF 
 1970 -0.006 (-0.015, 0.003) -0.008 (-0.017, 0.001) -0.005 (-0.019, 0.009) 
 1980 0.002 (-0.010, 0.014) -0.002 (-0.014, 0.011) 0.005 (-0.014, 0.024) 
  1990 -0.007 (-0.022, 0.009) -0.008 (-0.024, 0.008) -0.007 (-0.031, 0.017) 
a aPD: adjusted prevalence difference; CI: confidence interval; REF: referent group 
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Supplemental Table 4.2. Sensitivity analyses for referent groups: age, period, and cohort effects 
on prevalence of past-month cannabis use, aPR (95% CI)a 
Parameter Category Original analysis Sensitivity 1b Sensitivity 2c 
Age 15-17 1.97 (1.72, 2.25) REF 1.97 (1.72, 2.25) 
 18-21 2.91 (2.57, 3.30) 1.48 (1.43, 1.53) 2.91 (2.57, 3.30) 
 22-25 2.28 (2.03, 2.57) 1.16 (1.11, 1.21) 2.28 (2.03, 2.57) 
 26-29 1.67 (1.49, 1.87) 0.85 (0.80, 0.90) 1.67 (1.49, 1.87) 
 30-34 1.34 (1.20, 1.50) 0.68 (0.64, 0.73) 1.34 (1.20, 1.50) 
  35-49 REF 0.51 (0.44, 0.58) REF 
Period 2002 REF 0.86 (0.80, 0.92) 1.11 (1.05, 1.17) 
 2003 0.99 (0.94, 1.04) 0.85 (0.79, 0.91) 1.10 (1.04, 1.16) 
 2004 0.92 (0.87, 0.97) 0.79 (0.74, 0.84) 1.02 (0.97, 1.08) 
 2005 0.90 (0.85, 0.95) 0.78 (0.73, 0.83) REF 
 2006 0.91 (0.86, 0.96) 0.78 (0.73, 0.83) 1.00 (0.95, 1.06) 
 2007 0.91 (0.86, 0.96) 0.78 (0.73, 0.83) 1.00 (0.95, 1.06) 
 2008 0.92 (0.87, 0.97) 0.79 (0.74, 0.84) 1.02 (0.96, 1.08) 
 2009 1.00 (0.94, 1.06) 0.86 (0.81, 0.91) 1.11 (1.05, 1.17) 
 2010 1.03 (0.97, 1.08) 0.88 (0.83, 0.93) 1.14 (1.08, 1.20) 
 2011 1.05 (0.99, 1.11) 0.90 (0.86, 0.95) 1.16 (1.10, 1.23) 
 2012 1.06 (0.99, 1.13) 0.91 (0.87, 0.95) 1.17 (1.10, 1.25) 
 2013 1.08 (1.01, 1.15) 0.93 (0.88, 0.97) 1.19 (1.12, 1.27) 
  2014 1.16 (1.09, 1.24) REF 1.29 (1.21, 1.37) 
Cohort 1960 REF 0.88 (0.76, 1.04) REF 
 1970 1.09 (0.96, 1.24) 0.97 (0.89, 1.04) 1.09 (0.96, 1.24) 
 1980 1.21 (1.05, 1.39) 1.07 (1.03, 1.12) 1.21 (1.05, 1.39) 
  1990 1.13 (0.97, 1.32) REF 1.13 (0.97, 1.32) 
a aPR: adjusted prevalence ratio CI: confidence interval; REF: referent group  
b Sensitivity analysis 1: referent groups are opposite of original analysis 
c Sensitivity analysis 2: referent groups are groups with lowest past-month marijuana use 
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Supplemental Table 4.3. Sensitivity analyses for categorization: age, period, and cohort effects 
on prevalence of past-month cannabis use, aPR (95% CI)a 
Parameter Category Sensitivity 3b Sensitivity 4c 
Age 15 1.04 (0.53, 2.04) REF 
 16 1.56 (0.81, 3.01) 1.50 (1.25, 1.81) 
 17 1.94 (1.01, 3.70) 1.86 (1.56, 2.22) 
 18 2.20 (1.17, 4.16) 2.12 (1.78, 2.52) 
 19 2.35 (1.26, 4.37) 2.26 (1.88, 2.70) 
 20 2.33 (1.26, 4.30) 2.24 (1.85, 2.71) 
 21 2.22 (1.21, 4.07) 2.14 (1.75, 2.6) 
 22-23 1.97 (1.10, 3.55) 1.90 (1.52, 2.35) 
 24-25 1.70 (0.96, 3.00) 1.63 (1.27, 2.1) 
 26-29 1.39 (0.80, 2.40) 1.22 (100, 1.78) 
 30-34 1.17 (0.71, 1.94) 1.13 (0.78, 1.62) 
  35-49 REF 0.96 (0.49, 1.89) 
Period 2002-03 REF 0.92 (0.74, 1.14) 
 2004-05 0.91 (0.82, 1.01) 0.83 (0.69, 1.01) 
 2006-07 0.88 (0.78, 0.99) 0.80 (0.68, 0.95) 
 2008-09 0.93 (0.81, 1.07) 0.85 (0.74, 0.98) 
 2010-11 1.00 (0.84, 1.18) 0.91 (0.81, 1.03) 
 2012-13 1.01 (0.84, 1.23) 0.93 (0.83, 1.04) 
  2014 1.09 (0.88, 1.36) REF (REF, REF) 
Cohort 1960-64 REF 0.71 (0.3, 1.68) 
 1965-69 1.01 (0.58, 1.76) 0.72 (0.33, 1.59) 
 1970-74 1.13 (0.63, 2.03) 0.81 (0.49, 1.34) 
 1975-79 1.35 (0.68, 2.67) 0.97 (0.67, 1.38) 
 1980-84 1.46 (0.72, 2.98) 1.04 (0.80, 1.36) 
 1985-89 1.53 (0.72, 3.26) 1.09 (0.90, 1.32) 
 1990-94 1.50 (0.67, 3.36) 1.07 (0.94, 1.22) 
  1995-99 1.40 (0.60, 3.29) REF (REF, REF) 
a aPR: adjusted prevalence ratio; CI: confidence interval; REF: referent group 
b Sensitivity analysis 3: finer age categories, two-year period categories, 5-year cohort categories 
c Sensitivity analysis 4: finer age categories, two-year period categories, 5-year cohort categories, opposite 
referent groups as original analysis 
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CHAPTER 5: PATERNAL CANNABIS USE AND RISK OF BIRTH 
DEFECTS IN THE NATIONAL BIRTH DEFECTS PREVENTION STUDY2 
5.1 Introduction 
Cannabis is the most commonly used illicit drug among men of reproductive age in the 
United States [3, 167]. As of 2015, an estimated 1 in 5 young men (aged 18-25) had used 
cannabis in the past month [167, 168]. Moreover, cannabis attitudes among young adults 
continue to move towards greater acceptance. The percentage of young adults who perceive 
“great risk from regular use” has drastically decreased in the past decade [9, 10]. Policies on 
cannabis legality are also rapidly changing. To date [as of December 2017], over half of US 
states have legalized medical use, eight states have legalized recreational use, and other states 
have legislation pending [169, 170]. Considering the increasing prevalence of use, changing 
social norms, and evolving policies of cannabis use, we must better understand how cannabis 
potentially impacts male reproductive health.  
A growing literature has shown that cannabis use has adverse effects on various aspects 
of semen quality [21, 55, 73, 74, 79, 171]. Most notably, a recent epidemiologic study of 1215 
young Danish men found that regular cannabis use significantly lowered sperm concentration 
and sperm count [21]. In response to this study, Eisenberg et al. published a commentary in the 
American Journal of Epidemiology stressing the need for more research on the effect of cannabis 
on male reproductive health [75]. The main psychoactive component of cannabis – 
tetrahydrocannabinol (THC) – interacts with the human endocannabinoid system, specifically 
                                                     
2 This chapter will be submitted to the American Journal of Epidemiology. 
 87 
CB1 and CB2 receptors. Human studies have shown that CB1 activation increases the proportion 
of immobile sperm, and CB2 activation increases the proportion of lower motility sperm [77]. 
Mouse studies have shown that CB1 receptors – which are significantly activated by THC – 
influence chromatin remodeling in sperm, suggesting that cannabis has potential epigenetic 
effects on sperm cells [22].  
 Although the effect of cannabis on sperm quality has been demonstrated, very little 
research has focused on the potential effects of paternal preconception cannabis use on 
embryonic development. Since cannabis affects semen quality, it warrants investigation as a 
potential risk factor for birth defects [5, 23]. Major birth defects, defined as a structural 
malformation with a significant impact on the health and development of a child, are the leading 
cause of infant mortality and lifelong disability [24, 25] in the U.S. While some genetic and 
environmental risk factors have been identified, little is known about the etiology of most birth 
defects. Though most research has focused on maternal risk factors, epidemiologic investigations 
have shown that paternal exposures (e.g. cigarette smoking, occupational exposures) during the 
preconception period may increase risk of birth defects [26-29, 172, 173].  
Three previous studies investigating the association between paternal cannabis use and 
subsequent risk of specific birth defects produced mixed results [30-32]. Shaw et al. (1996) 
found that paternal cannabis use was not associated with neural tube defects (NTDs) (cOR: 0.86, 
95% CI: 0.63, 1.2; no adjusted estimates reported) in the California Birth Defects Monitoring 
program [32]. Ewing et al. (1997) and Wilson et al. (1998) both investigated the association 
between paternal cannabis use and specific types of congenital heart defects (CHDs) in the 
Baltimore-Washington Infant Study and found increased risk for isolated membranous 
ventricular septal defects and transposition of great arteries with intact ventricular septum [30, 
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31]. All three studies used maternal report of paternal cannabis use, and none investigated 
potential impacts of exposure misclassification. All studies were conducted in the late 1980s, but 
cannabis potency has considerably increased in the past two decades [137, 174, 175]. In 
summary, this small literature suggests potential increased risk for CHDs but is outdated and 
faces challenges with exposure measurement, appropriate confounder adjustment, and clinical 
case verification. Moreover, other defects besides CHDs and NTDs have not been investigated.  
Therefore, we aimed to investigate the association between paternal cannabis use during 
the preconception period and risk of 21 structural birth defect phenotypes in the National Birth 
Defects Prevention Study (NBDPS), a large national case-control study of risk factors for birth 
defects.  
5.2 Materials and methods 
5.2.1 Study design and population 
The National Birth Defects Prevention Study (NBDPS) is the largest and most 
comprehensive population-based case-control study of birth defects in the United States [123]. 
NBDPS has ten study centers located in geographically diverse parts of country (Arkansas, 
California, Georgia, Iowa, Massachusetts, North Carolina, New Jersey, New York, Texas, and 
Utah). During the study period of 1997-2011, approximately 6 million births occurred in the 
NBDPS catchment area.  
Study eligibility started with pregnancies ending on or after October 1, 1997, and 
concluded with pregnancies with estimated dates of delivery (EDD) on or before December 31, 
2011 eligible study sites.  A woman was ineligible to participate in the NBDPS if she already 
participated in the study with a previous pregnancy, could not complete the interview in English 
or Spanish, was incarcerated, or did not have legal custody of the infant. For three out of the ten 
centers, women under 18 years at the end of her pregnancy were ineligible [123]. Women were 
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excluded if they had participated with a previous pregnancy, were unable to complete the 
interview in English or Spanish, were incarcerated, or did not have legal custody of the infant. 
For this analysis, we additionally excluded pregnancies conceived from donor sperm (n=170). 
Details on the NBDPS study design and population have been previously published [123]. 
To focus on more prevalent defects and to ensure sufficient statistical power, analyses 
included only phenotypes represented by over 500 cases available in NBDPS. 
5.2.2 Case and control ascertainment 
The goal of NBDPS was to understand risk factors for birth defects with unknown 
etiologies. Therefore, cases were not eligible for NBDPS if they had a chromosomal anomaly, 
recognized single-gene disorder, or known teratogenic syndrome [123]. Cases are identified from 
state-level Birth Defects Surveillance programs, then undergo a rigorous verification process by 
clinical geneticists with expertise in birth defects phenotyping. Identified cases are contacted by 
mail or phone to request participation in the study. The NBDPS clinical geneticists developed 
guidelines that detailed the (1) inclusion and exclusion criteria for each defect eligible for the 
NBDPS; (2) rationale for including certain diagnostic codes for defects and related defects; (3) 
instructions and rationale for designating the final case classification (isolated, multiple, 
complex); and (4) instructions and recommendations to analysts on how the defect type could be 
analyzed in epidemiologic studies. Separate guidelines were developed for classifying congenital 
heart defects, since they are unique in etiology and clinical presentation [98]. All guidelines were 
consistent across study site to ensure that the classification process did not differ geographically 
or by clinical geneticist. Most centers included stillbirths and induced abortions in the case 
group, in addition to live births [98, 176].  
Controls were randomly sampled live births selected from the source population that 
represents the geographic region and time period of cases. Mothers were contacted for 
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participation in the same way as cases (e.g. by mail and phone). If a potential control was later 
found to have an eligible birth defect, they were converted to a case. The monthly number of 
controls selected was proportional to the number of births in the same month in the previous year 
to minimize seasonal effects on control sampling. The study design used a 3:1 case-to-control 
ratio to ensure sufficient statistical power to investigate a wide variety of birth defect phenotypes 
[123].  
5.2.3 Exposure and covariate measurement 
Trained interviewers conducted a one-hour computer-assisted telephone interview 
(CATI) with each mother in the study, which asked detailed questions regarding diet, drug use, 
demographics, lifestyle factors, pregnancy history, fertility treatments, medical conditions, and 
paternal characteristics during the preconception and pregnancy periods. Interviews were 
scheduled at the mother’s convenience, offered in both English and Spanish, and sometimes 
completed over the course of multiple telephone calls. One section of the CATI asks women to 
report about the baby’s father, including information about demographics, family history, 
occupation, smoking, and substance use.  
For this analysis, the exposure of interest – preconception paternal cannabis use – is 
defined as ever/never use of marijuana during the 3-month period prior to conception. Data on 
potential confounders were ascertained from the CATI. 
5.2.4 Statistical analyses  
Regression 
Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) for the association between paternal preconception cannabis use 
(yes/no) and specific birth defect phenotypes (yes/no) while accounting for possible 
confounding. Since birth defects are etiologically heterogeneous, separate logistic models were 
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fit for each birth phenotype group. Congenital heart defects (CHDs) are clinically and 
etiologically distinct from non-heart defects and were therefore handled slightly differently in the 
analysis [98]. Non-heart defects were analyzed at the ‘isolated’ level to represent cases where 
only a single major defect was diagnosed, while CHDs were analyzed at the ‘simple isolated’ 
level to represent non-association and non-complex cases where only a single major defect was 
diagnosed. A directed-acyclic-graph (DAG) was used to identify potential confounders 
including: other paternal drug use, paternal age, paternal education, maternal cannabis use, other 
maternal drug use, maternal education, maternal cigarette smoking, maternal alcohol use, 
household income, and study site [177, 178]. All potential confounders were included in the final 
adjustment set, which was consistent across birth defect models. Gestational age at delivery and 
birth weight were not included in the adjustment set since they are potential mediators on the 
paternal cannabis-birth defects causal pathway [124, 125].  
Probabilistic bias analysis  
Since some degree of misclassification is expected in maternal report of paternal cannabis 
use, we conducted probabilistic bias analyses to assess how various types of exposure 
misclassification would impact our results. Whereas simple bias analyses simulate results under 
specified parameters (e.g. exact sensitivity and specificity of observed exposure), probabilistic 
bias analyses take into account uncertainty of exposure correction by drawing from a distribution 
of parameters (e.g. distribution of probable sensitivity and specificity values). This latter 
approach was well-suited for our analysis since no validation data to deterministically specify 
accuracy of exposure were available. More details about this approach have been previously 
published [132-134]. We created a SAS macro to estimate results under positive predictive 
values (PPVs) and negative predictive values (NPVs) drawn from a specified trapezoidal 
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distribution, using bootstrap methods to appropriately estimate confidence intervals. We 
conducted the bias analyses for both differential and non-differential misclassification for 
adjusted results prior to multiple imputation. We conducted bias analyses for a six non-heart 
defects and two heart defects to get a sense of the magnitude and direction of the bias. Details of 
the probabilistic bias analysis are provided in Supplemental Table 5.1.    
5.3 Results 
Descriptive results  
 
A total of 22,522 cases and 11,798 controls were eligible for analysis. Paternal cannabis 
use during the 3-month period prior to conception was reported for 8.8% of control fathers and 
10.4% of eligible case fathers. While paternal and maternal cannabis use were correlated (r=0.49; 
r2=0.24), paternal use was higher than maternal use during pregnancy (5.0%) among controls. 
Cases and controls were similar in terms of maternal and paternal age, education, and household 
income (see Table 5.1). Among controls, exposure prevalence differed across study site, with the 
highest prevalence in Arkansas (13.0%) and the lowest in Utah (4.4%). Exposure prevalence also 
shifted over the course of the study period from 4.0 % in 1997 to 9.6% in 2011.  
Main effects 
 
Any paternal cannabis use during the 3-month preconception period was crudely 
associated with anencephaly (OR: 1.43, 95% CI: 1.11, 1.84), cleft lip and palate (cOR: 1.21, 
95% CI: 1.04, 1.43), cleft lip alone (cOR: 1.34, 95% CI: 1.09, 1.63), transverse limb deficiency 
(cOR: 1.41, 95% CI: 1.11, 1.79), diaphragmatic hernia (cOR: 1.28, 95% CI: 1.02, 1.61), and 
gastroschisis (cOR: 3.07, 95% CI: 2.66, 3.54) (see Table 5.2). After adjustment, four results had 
suggestive associations including: diaphragmatic hernia (aOR: 1.33, 95% CI: 0.99, 1.80), cleft 
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lip alone (aOR: 1.23, 95% CI: 0.95, 1.60), gastroschisis (aOR: 1.26, 95% CI: 1.00, 1.52), and 
hypoplastic left heart syndrome (aOR: 1.38, 95% CI: 0.99, 1.24).   
Probabilistic bias analysis  
Table 5.3 shows predicted effect estimates under pre-specified trapezoidal distributions 
for PPV and NPV for non-differential and differential exposure misclassification frameworks, 
alongside adjusted results from complete-case analyses. Generally, bias analyses shifted odds 
ratios towards the null or remained consistent. The largest shift in magnitude was observed for 
diaphragmatic hernia, where the original effect estimate aOR: 1.33 (95% CI: 0.99, 1.80) shifted 
to aOR: 1.08 (95% CI: 0.84, 1.40) and aOR: 1.03 (95% CI: 0.83, 1.27) under assumptions of 
non-differential and differential misclassification, respectively. A similar shift in magnitude was 
seen for cleft lip alone, gastroschisis, and hypoplastic left heart syndrome.  
5.4 Discussion 
In a comprehensive case-control study of birth defects, we found that reported paternal 
cannabis use during the 3-month period prior to conception was associated with slightly 
increased risk of diaphragmatic hernia, gastroschisis, cleft lip alone, and hypoplastic left heart 
syndrome. This is the first study to investigate the association between paternal cannabis use and 
birth defects since the 1980s, since then cannabis potency has changed considerably [136, 137, 
174]. These associations persisted after adjustment for important confounders, and remain 
unchanged after probabilistic bias analyses under a range of plausible assumptions about the 
structure of any anticipated exposure misclassification. However, these positive findings must be 
balanced with the null effects observed for 19 other birth defects in this analysis.  
Our findings are consistent with some of the previous investigations of paternal cannabis 
use and birth defects. Shaw et al. (1996) found that paternal preconception cannabis use was not 
associated with neural tube defects (NTD) in California from 1989-1991 (cOR: 0.86, 95% CI: 
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0.63, 1.2) [32]. We had the ability to investigate more specific NTD phenotypes and found 
similar null results (anencephaly and craniorachischisis: aOR: 1.14, 95% CI: 0.80, 1.64; spina 
bifida: aOR: 1.02, 95% CI: 0.78, 1.33). Ewing et al. (1997) and Wilson et al. (1998) found 
increased risk for two specific CHDs in the Baltimore-Washington Infant Study (BWIS) from 
1981-1989: Ventricular septal defects (VSDs) and Transposition of great arteries with intact 
ventricular septum (TGA) [30, 32]. These results are somewhat inconsistent with our findings: 
we found slightly increased risk of hypoplastic left heart syndrome, but not of the 8 remaining 
CHD phenotypes we investigated. However, all three previous studies had very limited sample 
size (e.g. the BWIS study had only 26 exposed cases for TGAs) and lacked sufficient adjustment 
for important confounders. No previous studies investigated other defects besides NTDs and 
CHDs, so our positive findings for gastroschisis, diaphragmatic hernia, and cleft lip alone are 
novel contributions to the literature.  
Epidemiologic and animal studies have consistently shown that cannabis use can 
adversely affect semen quality, specifically sperm count and motility, but the epigenetic effects 
are less clear [21, 75]. A recent study in mice showed that the CB1 receptor, an important part of 
the endocannabinoid system that is activated by THC, influences chromatin remodeling in sperm 
[22, 79, 179]. This suggests that cannabis has the potential to induce epigenetic changes on 
sperm. However, additional research is needed to confirm and clarify this effect. Although 
epigenetic pathways are the most likely mechanism for this association given the epigenetic 
etiologies for many birth defects, another potential mechanism is secondhand cannabis smoke 
exposure to the mother. This assumes that cannabis was consumed via smoking and occurred 
around the mother during early pregnancy. However, a study of maternal cannabis use in 
NBDPS did not find increased risk for diaphragmatic hernia (aOR: 1.3, 95% CI: 0.8–2.2) or 
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gastroschisis (aOR: 1.3, 95% CI: 0.9, 1.8), suggesting that mechanisms for paternal versus 
maternal cannabis use may be distinct from one another [16], at least for some birth defects. 
Our findings are also inconsistent with literature on other male-mediated substances than 
may cause birth defects. A study of paternal cigarette smoking during the peri-conception period 
in a Chinese population found increased risk of conotruncal heart defects, septal defects, and left 
ventricular outflow tract obstructions, but did not investigate non-heart defects [180]. Savitz et 
al. found that paternal cigarette smoking was associated with increased risk of cleft lip with or 
without cleft palate, hydrocephalus, ventricular septal defects, and urethral stenosis in a U.S. 
population [181]. Shaw et al. found that paternal heroin use was associated with increased risk of 
NTDs (OR: 4.6, 95% CI: 0.92, 30.6), but few other studies have investigated paternal drug use 
[32]. Defects identified from these paternal smoking and drug use studies do not overlap with the 
four defects we identified as associated with paternal cannabis use (diaphragmatic hernia, 
gastroschisis, cleft lip alone, hypoplastic left heart syndrome), suggesting these mechanisms may 
also be distinct. 
Strengths of this study include its use of population-based controls, standardized clinical 
verification of cases, large sample size, and analytic methods to handle potential 
misclassification bias. The NBDPS identifies controls from birth records that represent the 
source population that gave rise to cases, thus providing a population-based control group that 
results in less potential for selection bias, compared to clinical or convenience-based control 
sampling [182, 183]. The NBDPS protocol includes a rigorous verification process for all 
potential cases, where clinical geneticists confirm exact birth defect diagnosis [123]. This 
detailed case classification increases phenotypic and etiologic homogeneity within birth defect 
group. Additionally, the sheer sample size of the NBDPS population allows for sufficiently-
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powered analysis of rare birth defect phenotypes [123]. Since we only included phenotypes with 
at least 500 eligible cases, we had sufficient sample size for all analyses. Finally, we had the 
ability to control for important confounders that previous studies lacked, like maternal cannabis, 
other maternal/paternal drug use, and maternal/paternal education.  
A major limitation of this study is our exposure measurement. While exposure was asked 
in reference to the etiologically-relevant timeframe, mothers reported retrospectively on paternal 
exposure and is subject to increased measurement error. Mothers may not have known fathers’ 
true cannabis use patterns, or they may have misreported due to recall error or social desirability 
bias [184-186]. However, superior exposure measures like urine or hair biomarkers were not 
available given the retrospective nature of this case-control study. After conducting probabilistic 
bias analyses to assess how exposure misclassification may impact results, we found that 
reasonable amounts of exposure misclassification – as defined by trapezoidal distributions for 
PPV and NPV – resulted in negligible changes in effect estimates. This held true for both non-
differential and differential (with respect to case-control status) structures of misclassification. 
Therefore, we feel that our results are robust to reasonable amounts of exposure 
misclassification. However, it is possible that the true misclassification was different than the 
distributions we assumed in our bias analysis. Future studies should consider conducting 
validation studies with biomarker data, or using both paternal self-report and maternal report 
together, to more accurately measure paternal cannabis use. Additionally, this study only 
assessed ever/never use of cannabis, but the true effect may differ by dosage, method of 
consumption (e.g. smoked, vaped, edibles), frequency of consumption (e.g. daily vs. monthly 
use) or strain (e.g. indica vs. sativa). Future studies should elucidate effect heterogeneity by these 
various types of exposure characteristics.  
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Our study may suffer from unmeasured confounding. Crude and adjusted results in our 
study differed meaningfully, suggesting that strong confounding was at play. While we were able 
to adjust for many important confounders -- such as maternal cannabis use, other maternal and 
paternal drug use, maternal and paternal education, and maternal income – results may still be 
biased by unmeasured or unknown confounders.  
Finally, a challenging limitation of this study is potential selection bias resulting from 
restricting on live birth [138, 187, 188]. If paternal cannabis use increased risk of early 
pregnancy loss, then we are investigating a select population of infants who were healthy enough 
to survive until birth. Eight out of ten NBDPS study sites included stillbirths and induced 
abortions in their case group, which somewhat mitigates the conditioning on live birth issue 
[123]. Furthermore, we may have selection bias from conditioning on conception, that is, if 
paternal cannabis use decreases the probability of getting pregnant, then we are investigating a 
select group of fathers that were able to conceive in the first place. The latter scenario is more 
likely, given that cannabis has proven effects on reducing sperm count and motility. 
Unfortunately, we lack the ability to quantify this particular bias. Future studies could measure 
exact effects of cannabis use on time-to-pregnancy and conduct bias analysis for selection bias 
given bounds of these selection effects.  
This is the first study to show that paternal cannabis use during the 3-month 
preconception period is associated with slightly increased risk of some structural birth defect 
phenotypes, including diaphragmatic hernia, gastroschisis, cleft lip alone, and hypoplastic left 
heart syndrome and not associated with other defects. These results warrant further investigation 
into cannabis as potential male-mediated teratogen, especially in light of changing cannabis 
policies and increases in prevalence of use among men of reproductive age.   
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Table 5.1. Study population characteristics by case status, n (%) 
  Cases* Controls 
Maternal characteristics    
Cannabis use†   
   Yes 1240 (5.7%) 577 (5.0%) 
   No 20709 (94.4%) 10909 (95.0%) 
   Missing 573 312 
Other drug use†§   
   Ever 340 (1.6%) 129 (1.1%) 
   Never 21618 (98.5%) 11365 (98.9%) 
   Missing 564 304 
Cigarette smoking†   
   Ever 4545 (20.7%) 2074 (18.0%) 
   Never 17428 (79.3%) 9424 (82.0%) 
   Missing 549 300 
Alcohol use†   
   Ever 8075 (36.9%) 4263 (37.2%) 
   Never 13822 (63.1%) 7197 (62.8%) 
   Missing 625 338 
Age at delivery   
   <20 2345 (10.4%) 1177 (10.0%) 
   20-29 11408 (50.7%) 5935 (50.3%) 
   30-39 8139 (36.1%) 4420 (37.5%) 
   ≥40 630 (2.8%) 266 (2.3%) 
   Missing 0 0 
Education   
   Less than high school 3713 (17.0%) 1905 (16.6%) 
   High school graduate 10776 (49.1%) 5346 (46.7%) 
  College graduate or higher 7407 (33.8%) 4202 (36.7%) 
   Missing 626 345 
Household annual income   
   <$10,000 4020 (19.5%) 2004 (18.9%) 
   $10,000-50,000 7061 (34.3%) 3862 (36.4%) 
   >$50,000 9509 (46.2%) 4759 (44.8%) 
   Missing 1932 1173 
Paternal characteristics   
Cannabis use‡   
   Yes 2203 (10.4%) 985 (8.8%) 
   No 19083 (89.7%) 10230 (91.2%) 
   Missing 1236 583 
Other drug use‡§   
   Yes 833 (3.8%) 301 (2.6%) 
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  Cases* Controls 
   No 20860 (96.2%) 11101 (97.4%) 
   Missing 829 396 
Cigarette smoking‡   
   Yes 2434 (28.2%) 1250 (26.4%) 
   No 6200 (71.8%) 3478 (73.6%) 
   Missing 13888 7070 
Age at delivery   
   <20 992 (4.6%) 543 (4.8%) 
   20-29 9556 (43.9%) 4944 (43.3%) 
   30-39 9193 (42.2%) 4961 (43.5%) 
   40-49 1876 (8.6%) 890 (7.8%) 
   ≥50 174 (0.8%) 75 (0.7%) 
   Missing 731 385 
Education   
   Less than high school 3769 (17.8%) 1813 (16.3%) 
   High school graduate 10648 (50.2%) 5335 (48.0%) 
   College graduate or higher 6797 (32.0%) 3974 (35.7%) 
   Missing 1308 676 
Infant characteristics   
Sex   
   Female 9043 (40.4%) 5781 (49.0%) 
   Male 13341 (59.6%) 6005 (51.0%) 
   Missing 138 12 
*Includes all cases included in analysis   
† Reflects use during pregnancy 
‡ Reflect use during periconception period (3-months prior to conception to infant birth)  
§ Any drug use includes any use of cocaine, crack, hallucinogens, heroin, or mushrooms 
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Table 5.2. Effect estimates of paternal preconception cannabis use and selected birth defect 
phenotypes 
 
Cases Controls 
  
Birth defect 
phenotype 
N (% exposed) N (% exposed) Crude OR (95% 
CI) 
Adjusted OR 
(95% CI)‡ 
Non-heart defects† 
      
Anencephaly and 
craniorachischisis 
656 (12.1%) 11799 (8.8%) 1.43  (1.11, 1.84) 1.14 (0.80, 1.64) 
Spina bifida 1292 (8.2%) 11799 (8.8%) 0.93  (0.75, 1.15) 1.02 (0.78, 1.33) 
Cleft palate alone 1625 (12.2%) 11799 (8.8%) 1.02  (0.84, 1.23) 0.88 (0.69, 1.12) 
Cleft lip with cleft 
palate 
2044 (10.6%) 11799 (8.8%) 1.21  (1.04, 1.43) 1.07 (0.87, 1.31) 
Cleft lip alone 1104 (11.5%) 11799 (8.8%) 1.34  (1.09, 1.63) 1.23 (0.95, 1.60) 
Esophageal atresia 762 (9.4%) 11799 (8.8%) 1.07  (0.83, 1.39) 1.17 (0.84, 1.63) 
Anorectal 
atresia/stenosis 
1090 (8.8%) 11799 (8.8%) 1.00  (0.80, 1.25) 1.18 (0.89, 1.56) 
Hypospadias 
second/third degree 
2582 (8.5%) 6005 (8.9%) 0.96  (0.81, 1.13) 1.03 (0.82, 1.29) 
Transverse limb 
deficiency 
731 (11.9%) 11799 (8.8%) 1.41  (1.11, 1.79) 1.20 (0.86, 1.66) 
Craniosynostosis 1622 (6.9%) 11799 (8.8%) 0.77  (0.63, 0.95) 0.92 (0.71, 1.20) 
Diaphragmatic 
hernia 
882 (11.0%) 11799 (8.8%) 1.28  (1.02, 1.61) 1.33 (0.99, 1.80) 
Gastroschisis 1449 (22.8%) 11799 (8.8%) 3.07  (2.66, 3.54) 1.23 (1.00, 1.52) 
Heart defects† 
      
DTransposition of 
the great arteries 
716 (8.4%) 11799 (8.8%) 0.95  (0.72, 1.26) 0.88 (0.62, 1.24) 
Hypoplastic left 
heart syndrome 
608 (10.7%) 11799 (8.8%) 1.24  (0.95, 1.63) 1.38 (0.99, 1.923) 
RVOT defects 1967 (9.8%) 11799 (8.8%) 1.13  (0.96, 1.34) 1.13 (0.91, 1.39) 
RVOT defects 
excluding Ebstein  
1829 (9.8%) 11799 (8.8%) 1.13  (0.95, 1.34) 1.14 (0.92, 1.42) 
Pulmonary valve 
stenosis 
1464 (9.5%) 11799 (8.8%) 1.08  (0.89, 1.31) 1.11 (0.88, 1.42) 
VSD 
perimembranous  
1408 (9.3%) 11799 (8.8%) 1.07  (0.88, 1.30) 1.04 (0.81, 1.33) 
VSD muscular 560 (8.0%) 11799 (8.8%) 0.90  (0.65, 1.24) 0.89 (0.60, 1.32) 
ASD secundum  2029 (10.0%) 11799 (8.8%) 1.15  (0.98, 1.35) 1.08 (0.88, 1.32) 
ASD NOS  516 (11.1%) 11799 (8.8%) 1.30  (0.97, 1.73) 0.70 (0.46, 1.06) 
*OR: odds ratio; CI: confidence interval; VSD: ventricular septal defect; ASD: atrial septal defect; 
NOS: not otherwise  
‡ Adjusted for paternal other drug use, age, education; maternal cannabis use, other drug use, cigarette 
smoking, age, education, alcohol use; household income; study site; study year 
†Heart defects are simple isolated; non-heart defects are isolated 
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Table 5.3. Probabilistic bias analysis under non-differential and differential exposure 
misclassification for effects of paternal cannabis use on select birth defects, OR (95% CI) 
Birth defect phenotype Original analysis‡ 
Non-differential 
probabilistic bias 
analysis‡ 
Differential 
probabilistic bias 
analysis‡ 
Non-heart defects    
Anencephaly and 
craniorachischisis 1.14 (0.80, 1.64) 0.98 (0.80, 1.21) 1.00 (0.76, 1.33) 
Spina bifida 1.02 (0.78, 1.33) 0.98 (0.78, 1.22) 0.98 (0.82, 1.16) 
Cleft palate alone 0.88 (0.69, 1.12) 0.98 (0.81, 1.19) 0.99 (0.86, 1.13) 
Cleft lip alone 1.23 (0.95, 1.60) 1.05 (0.90, 1.24) 1.02 (0.82, 1.26) 
Transverse limb deficiency 1.20 (0.86, 1.66) 1.06 (0.88, 1.29) 1.06 (0.79, 1.41) 
Diaphragmatic hernia 1.33 (0.99, 1.80) 1.08 (0.84, 1.40) 1.03 (0.83, 1.27) 
Gastroschisis 1.23 (1.00, 1.52) 1.06 (0.83, 1.35) 1.09 (0.88, 1.35) 
Heart defects    
DTransposition of the great 
arteries 0.88 (0.62, 1.24) 0.96 (0.74, 1.26) 0.99 (0.79, 1.24) 
VSD perimembranous  1.04 (0.81, 1.33) 1.01 (0.85, 1.20) 1.03 (0.83, 1.28) 
*OR: odds ratio; CI: confidence interval   
‡ Adjusted for paternal other drug use, age, education; maternal cannabis use, other drug use, 
cigarette smoking, age, education, alcohol use, househould income; study site 
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Supplemental Table 5.1. Specified trapezoidal distributions for positive predictive value (PPV) 
and negative predictive value (NPV) for probabilistic bias analyses under non-differential and 
differential exposure misclassfication  
    
Non-
differential Differential 
Case PPV Leftmost end of trapezoid (bottom) 0.95 0.95 
 Leftmost end of trapezoid (plateau) 0.98 0.98 
 Rightmost end of trapezoid (plateau) 0.99 0.99 
  Rightmost end of trapezoid (bottom) 1.00 1.00 
Case NPV Leftmost end of trapezoid (bottom) 0.50 0.50 
 Leftmost end of trapezoid (plateau) 0.70 0.70 
 Rightmost end of trapezoid (plateau) 0.90 0.90 
  Rightmost end of trapezoid (bottom) 0.99 0.99 
Control 
PPV Leftmost end of trapezoid (bottom) 0.95 0.80 
 Leftmost end of trapezoid (plateau) 0.98 0.90 
 Rightmost end of trapezoid (plateau) 0.99 0.98 
  Rightmost end of trapezoid (bottom) 1.00 1.00 
Control 
NPV Leftmost end of trapezoid (bottom) 0.50 0.50 
 Leftmost end of trapezoid (plateau) 0.70 0.75 
 Rightmost end of trapezoid (plateau) 0.90 0.85 
  Rightmost end of trapezoid (bottom) 0.99 0.85 
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CHAPTER 6: DISCUSSION 
6.1 Overview 
 State-level policies on medical and recreational cannabis legality have changed rapidly in 
the past decade, fueling a lively and important debate around the safety, merits, and health 
effects of cannabis use. In a climate where political ideologies and ignorance often direct policy 
decisions, sound science is needed to direct to the ongoing debate on cannabis use. While health 
effects of cannabis use remain unknown and vastly understudied, the reproductive health effects 
are especially understudied. This is of utmost public health concern, since cannabis use is 
prevalent and increasing among U.S. men and women of reproductive age and potential 
consequences on offspring may be severe.  
This dissertation sought to address the broader knowledge gap of the reproductive health 
effects of cannabis use by tackling two unanswered questions. Specifically, our first aim 
addressed how trends in past-month cannabis use correlate with the inter-related time factors of 
age, period, and cohort among U.S. men and women of reproductive age. These results elucidate 
demographic shifts in the prevalence of past-month cannabis use in this particular population and 
are designed to be nationally-representative. Our second aim assessed how paternal cannabis use 
during the 3-month preconception window affected risk of subsequent birth defects in the 
offspring. This is the first rigorous and adequately-powered study to address this study questions, 
and results from this aim contribute to our understanding of male-mediated teratogenicity of 
cannabis use. Ultimately, results from this dissertation contribute rigorous evidence to our 
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understanding of the reproductive health effects of cannabis use that may eventually influence 
clinical guidance and policy decisions regarding cannabis use.  
6.2. Aim 1 
6.2.1 Summary of findings  
Results from Aim 1 confirmed that cannabis use is prevalent and increasing among both 
men and women of reproductive age (15-49) in the United States, with approximately 12% 
reporting past-month use in 2014. Prevalence almost doubled among women aged 26-34 in 
particular, which reflects women with the highest birth rate. Age, period, and cohort each have 
independent effects on past-month cannabis use, with age having the strongest influences. When 
holding age and cohort constant, small but consistent period effects were observed. Most 
notably, period effects – which arose from time-dependent socio-cultural factors – were strongest 
for 2013 and 2014. State-level cannabis legalization in 2012 may partly explain these recent 
national period effects, though recent period effects also fit a larger trend of steady increases in 
cannabis use in the past decade. Understanding trends in cannabis use among women and men of 
reproductive age is an essential step toward developing health policy, health education, and 
targeted interventions to mitigate potential adverse reproductive health effects from cannabis use.  
6.2.2 Strengths and limitations 
Strengths 
This was the first study to examine age, period, and cohort effects on cannabis use in the 
United States since the first states legalized recreational use of cannabis in 2012 and the first 
study to explore differences among men and women of reproductive age. Laws and social norms 
have changed drastically since the last APC study reported on trends through 2009 [10, 157, 
162].  The most notable change was in 2012 with the first state legalization of recreational 
cannabis use, so it is timely to examine time trends and drivers those trends over the past seven 
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years [158]. Our efforts to understand trends among individuals of reproductive age are crucial to 
public health guidelines and planning, especially in light of the growing evidence of adverse 
reproductive health effects of cannabis use. Moreover, we have investigated past-month use, 
which provides a more temporally-relevant measure of use with regard to reproductive health 
effects than would be available from previous studies that evaluated past-year cannabis use [164-
166]. Since patterns for past-year and past-month use are distinct, our investigation of age-
period-cohort effects for past-month cannabis use are novel and may portray age, period, and 
cohort effects for a more biologically-relevant exposure. Finally, we were able to address this 
study aim using data from the National Survey of Drug Use and Health, an extremely large and 
comprehensive survey designed to be nationally representative. This data source, along with the 
analytic techniques in our analysis to appropriately handle the study’s complex survey 
weighting, provide us external validity, e.g. the ability to generalize our results to the broader 
target population of all U.S. men and women of reproductive age.  
Limitations 
Due to the data source, we had to rely on self-report of cannabis use. Self-report of 
cannabis may be under-estimate exposure, and the extent of measurement error may differ by 
age and gender. In fact, a study was just published during the writing of this dissertation thesis 
that shows how true cannabis exposure (measured by toxicology reports) is almost twice as high 
as self-reported cannabis use among pregnancy women in the Kaiser Permanente population in 
California, USA [189]. In addition, our results could be vulnerable to time-varying changes in 
reporting accuracy either by all participants or by participants of specific age groups: if study 
participants in later years are more comfortable reporting true cannabis use, we may mistake 
increased reporting for increases in actual prevalence. These concerns may be mitigated by 
 106 
measures taken within the NSDUH data collection protocol to improve the accuracy of self-
report, including: anonymous reporting without face-to-face interactions with the interviewer, 
reminders of anonymity, and a repeated follow-up approach to minimize non-response.  
This study also has limitation in ascertain cohort effects. By restricting to a 13-year 
period (2002 to 2014), we are ‘capturing’ each birth cohort at specific ages. For example, 
individuals born in 1965 would be captured in our study at ages 37 to 49, whereas individuals 
born in the 1990 would be captured at ages 17 to 29. Since cannabis use is most prevalent among 
young adults, we may be missing the heaviest cannabis use for the 1960 and 1970 birth cohorts. 
We adjusted for period and age in the cohort effect estimates, which may mitigate this issue by 
providing cohort trends averaged over all period and age groups, but generalization of our results 
beyond this sample is limited.  Longer study periods could help corroborate estimates of cohort 
effects in past-month cannabis use. Additionally, more recent data would allow for a longer 
assessment of period effects after state-level legalization in 2012.  
Finally, we were unable to investigate effect-measure modification by state because the 
public-access NSDUH files do not include data on participants’ residence. Many states 
decriminalized possession and legalized medical and/or recreational use of cannabis over the 
study period, which likely results in effect heterogeneity by state specifically for the period 
effect. Additionally, it would have been interesting to descriptively assess how trends in past-
month cannabis use different across state, and how the gender difference in prevalence of use 
varied across state. Future studies could look at state-specific data to elucidate how period effects 
differ geographically and by type of legislation change.  
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6.2.3 Future directions 
To better characterize age, period, and cohort effects of past-month cannabis use, future 
studies should consider conducting state-specific analyses. Since state-level policies on medical 
use, recreational use, and criminalization have changed dramatically in the past decade and differ 
by state, there is likely effect heterogeneity of trends and age, period, cohort effects by state that 
we missed in Aim 1. Moreover, state-specific analyses may be more useful to state-level policy 
development and decision-making.  
Future studies could also examine trends using more accurate measures of cannabis use, 
like biomarker measure or toxicology data. There is an important tradeoff when deciding 
between self-report or biologic measures of cannabis use. Biologic measures are much more 
challenging and costly to obtain, and nearly impossible to obtain in a nationally-representative 
way. However, biologic measures have much higher validity and therefore more accurately 
capture true exposure. In our age-period-cohort analysis, we had no way to parsing out changes 
in trends into changes in actual use or changes in reporting bias (e.g. perhaps people felt more 
comfortable reporting in study years). Moreover, a paper just published in JAMA shows how 
toxicology measure of prenatal cannabis use are almost twice as high as self-report measures 
[189], thus highlighting the need to validate our results using biologic measure of cannabis use. 
6.3 Aim 2 
6.3.1 Summary of findings  
Results from Aim 2 show that paternal cannabis use during the 3-month period prior to 
conception was associated with slightly increased risk of diaphragmatic hernia, gastroschisis, 
cleft lip alone, and hypoplastic left heart syndrome in a comprehensive case-control study of 
birth defects. This was the first study to investigate the association between paternal cannabis use 
and birth defects since the 1980s, since when cannabis potency has changed considerably [136, 
 108 
137, 174]. These findings persisted after adjustment for important confounders, imputation for 
missing confounder data, and probabilistic bias analyses for exposure misclassification. 
However, these positive findings must be balanced with the null effects observed for 19 other 
birth defects in this analysis.  
Our findings are somewhat inconsistent with previous investigations of paternal cannabis 
use and birth defects. While our null results for neural tube defects were consistent with findings 
from Shaw et al. (1996), our null results for subtypes of congenital heart defects (CHDs) were 
inconsistent with the increased risk for specific CHD subtypes found by Ewing et al. and Wilson 
et al. However, all three previous studies has very limited sample size (e.g. the BWIS study had 
only 26 exposed cases for TGAs) and lacked sufficient adjustment for important confounders. 
No previous studies investigated other defects besides NTDs and CHDs, so our positive findings 
for diaphragmatic hernia, gastroschisis, and cleft lip alone are novel contributions to the 
literature. Our findings are also inconsistent with literature on other male-mediated substance use 
teratogens. Previous studies found that paternal smoking was associated with increased risk of 
cleft lip with or without cleft palate and specific CHD subtypes [28, 181]. Another study found 
that paternal heroin use was associated with increased risk of NTDs, but few other studies have 
investigated paternal drug use [32]. Defects identified from these paternal smoking and drug use 
studies do not overlap with the two defects we identified as associated with paternal cannabis use 
(diaphragmatic hernia, gastroschisis), suggesting these mechanisms may also be distinct. 
In conclusion, this is the first study to show that paternal cannabis use during the 3-month 
preconception period is associated with slightly increased risk of four structural birth defect 
phenotypes: diaphragmatic hernia, gastroschisis, cleft lip alone, and hypoplastic left heart 
syndrome. In contrast to previous studies, only one association with congenital heart defects 
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(CHDs) were observed. These results warrant further investigation into cannabis as potential 
male-mediated teratogen, especially in light of changing cannabis policies and increases in 
prevalence of use among men of reproductive age.  
6.3.2 Strengths and limitations 
Strengths 
 
Strengths of this study include its use of population-based controls, clinical verification 
of cases, large sample size, and analytic methods to handle potential biases. The National Birth 
Defects Prevention Study (NBDPS) identifies controls from birth records that represent the 
source population that gave rise to cases, thus providing a population-based control group that 
results in less potential for selection bias, compared to clinical or convenience-based control 
sampling [182, 183]. The NBDPS protocol includes a rigorous verification process for all 
potential cases, where clinical geneticists confirm exact birth defect diagnosis [123]. This 
detailed case classification minimizes potential for outcome measurement error and allows for 
more specific case identification compared to other birth defect studies. Additionally, the sheer 
sample size of the NBDPS population allows for sufficiently-powered analysis of rare birth 
defect phenotypes [123]. Since we only includes phenotypes with at least 500 eligible cases, we 
had sufficient power for all analyses. Finally, we had the ability to control for important 
confounders that previous studies lacked, like maternal cannabis and other maternal/paternal 
drug use. Our crude and adjustment results were meaningfully different, suggesting these 
covariates were likely confounding the association. 
Limitations 
A major limitation of this study is our exposure measurement. While exposure was asked 
in reference to the etiologically-relevant timeframe, mothers reporting retrospectively on paternal 
exposure was subject to measurement error. Mothers may not have known fathers’ true cannabis 
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use patterns, or they may have misreported due to recall error or social desirability bias [184-
186]. However, superior exposure measures like urine or hair biomarkers were not possible 
given the retrospective nature of this case-control study. After conducting probabilistic bias 
analyses to assess how exposure misclassification may impact results, we found that reasonable 
amounts of exposure misclassification – as defined by trapezoidal distributions for PPV and 
NPV – resulted in negligible changes in effect estimates. This held true for both non-differential 
and differential structures of misclassification. Therefore we feel that our results are robust to 
reasonable amounts of exposure misclassification. However, it is possible that the true 
misclassification was different than the distributions we assumed in our bias analysis. Future 
studies should consider conducting validation studies with biomarker data, or using both paternal 
self-report and maternal report together, to more accurately measure paternal cannabis use.  
Another limitation of this study is potential selection bias resulting from conditioning on 
live birth [138, 187, 188]. If paternal cannabis use increased risk of early pregnancy loss, then we 
are investigating a select population of infants who were healthy enough to survive until birth. 
Eight out of ten NBDPS study sites included stillbirths and induced abortions in their case group, 
which somewhat mitigates the conditioning on live birth issue [123]. Furthermore, we may have 
selection bias from conditioning on conception: if paternal cannabis use decreases the probability 
of getting pregnant, then we are investigating a select group of fathers that were able to conceive 
in the first place. The latter scenario is more likely, given that cannabis has proven effects on 
reducing sperm count and motility. Unfortunately we lack the ability to quantify this particular 
bias. Future studies could measure exact effects of cannabis use on time-to-pregnancy and 
conduct bias analysis for selection bias given bounds of these selection effects.  
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Finally, this study only assessed ever/never use of cannabis, but the true effect may differ 
by dosage, method of consumption (e.g. smoked, vaped, edibles), frequency of consumption (e.g. 
daily vs. monthly use) or strain (e.g. indica vs. sativa). In other words, the true effect of paternal 
cannabis use may depend on how it was consumed, what exact dosage or type of cannabis was 
consumed, or exactly when prior to conception exposure occurred – but our study cannot identify 
effect heterogeneity. Moreover, this study design cannot parse out the effects of chronic cannabis 
use (e.g. men who used cannabis daily for ten years) versus cannabis use specific during the 3-
month preconception period. We lacked data on men’s prior cannabis use patterns, so we were 
unable to know if ‘exposed’ men in our study were regular cannabis users or if their exposure 
was limited to the preconception period. Given the animal research on how THC may affect male 
reproductive organs and sperm quality, it is possible – though not proven – that cannabis has 
effects that persist after the 3-month spermatogenesis cycle. Additional biologic research is 
needed to elucidate how long the effects of cannabis on male reproductive health can last. In the 
meantime, future epidemiologic studies should consider ascertaining information on men’s 
previous cannabis patterns, in addition to their exposure during the preconception period, so 
analyses can parse out these two distinct exposure profiles.   
6.3.3 Future directions 
Since this is the first study since the 1980’s on paternal preconception cannabis use and 
risk of birth defects, many future studies are needed to validate and clarify our findings. First, 
future studies should first investigate this association using biologic measures of exposure. As 
explained earlier, biologic measure of cannabis use are more valid than self-report (or in this 
case, maternal report of paternal exposure). While we conducted rigorous bias analysis to assess 
impacts of exposure misclassification, it is always better to have less measurement error in the 
first place. Given the case-control nature of the study design, any measurement bias may be 
 112 
exacerbated if cases and controls have different formats of measurement error, thus highlighting 
the need for more valid exposure measures in future studies. Future studies should consider 
measuring THC in urine or hair, though studies would need a prospective design to ascertain 
these biologic measures of exposure.  
Second, future studies should consider using alternative study designs to address the 
selection bias issue discussed in section 6.3.1 (Strengths & Limitations – Aim 2). Our limitation 
was conditioning on conception (and survival to a certain point in pregnancy), which is 
challenging to address. However, a time-to-pregnancy study of couples trying to conceive could 
theoretically measure paternal cannabis use at multiple time points, and if conception occurs, 
follow up the infants for adverse birth outcomes. While the paternal cannabis use-birth defects 
association would still be measured in a population conditioned on conception, this study design 
would add valuable information on the effects of male cannabis use on likelihood to conceive 
and time-to-pregnancy, which helps frame and quantify the selection bias. Analytic methods – 
such as simulations or bias analyses – could then estimate how this selection bias may, or may 
not, influence effect estimates.  
Finally, our study only examined ever/never use of cannabis during the preconception 
period, but the true effect may be specific to certain dosages, strains, methods of consumption, or 
timing of use. Future studies should ascertain more specific information on exposure, so they can 
examine effect-measure modification by these important factors. While dosage has historically 
been difficult to ascertain since most users are unaware of the exact contents and dosage of the 
cannabis they use [44], future studies should consider taking advantage of THC and CBD 
concentration labeling that is now common in states with legal recreational cannabis.  
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6.4 Conclusions  
While both dissertation aims address the broad research area of cannabis use and 
reproductive health, each aim is quite distinct in its design, analytic methods, and study question 
it addressed. Aim 1 describes trends in past-month cannabis use in the past decade in our 
population of interest (men and women of reproductive age) using a technique from 
demography: the age-period-cohort analysis. This aim is descriptive in nature and helps elucidate 
shifting trends and life-course patterns of cannabis use. Then, Aim 2 quantifies the effect of 
preconception paternal cannabis use on 21 types of birth defect phenotypes. This aim is causal in 
nature and contributes compelling evidence about the potential male-mediated teratogenicity of 
cannabis use. Notably, the first aim is focused on men and women of reproductive age, 
regardless of their parity, pregnancy status, or intentions to reproduce, while the second aim is 
focused on male exposure during the 3-month preconception period among men who were able 
to conceive. Together, these two aims complement each other by describing trends in exposure 
broadly among populations of reproductive age, then estimating the causal effect of paternal use 
on an important adverse birth outcome, both in U.S. populations.   
In a nationally-representative study of U.S. men and women of reproductive age, we 
found that that past-month cannabis use was prevalent and increased from 9.2% in 2002 to 
12.3% in 2014. While distinct age, period, and cohort effects were observed, age remains the 
strongest correlate of past-month use. Despite documented increases in the prevalence of use and 
rapidly changing state-level policies, little is known about the reproductive health effects of 
cannabis use. In a rigorous U.S. case-control study of 21 birth defect phenotypes, we found that 
paternal cannabis use during the 3-months prior to conception was associated with slightly 
increased risk of diaphragmatic hernia, gastroschisis, cleft lip alone, and hypoplastic left heart 
syndrome. These associations are novel and inconsistent with previous studies. While future 
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studies are needed to validate and expand upon our results, these findings indicate that paternal 
cannabis use during the preconception period may increase of specific birth defects. As cannabis 
policies and social norms continue to change, more research is urgently needed to understand 
how cannabis use affects reproductive health and how patterns of cannabis use are changing in 
the population.  
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APPENDIX A: EXPOSURE PREVALENCE BY STUDY YEAR AND SITE IN NBDPS 
Table A.1. Prevalence of paternal cannabis use during the 3 months prior to conception in the National Birth Defects Prevention 
study from 1997 to 2011 (%) 
  Arkansas California Iowa Massachusetts New Jersey New York Texas CDC/Atlanta North Carolina  Utah 
All years 13.0 8.8 6.4 7.7 5.6 10.0 9.1 11.4 7.5 4.4 
1997 NA 0 0 0 NA 0 6.7 23.1 NA NA 
1998 11.4 5.4 5.6 8.8 0.9 10.8 16.1 10.8 NA NA 
1999 13.3 6.5 6.1 12.0 3.3 10.3 9.7 9.2 NA NA 
2000 7.8 9.2 9.5 10.3 7.4 8.4 9.6 5.7 NA NA 
2001 7.0 11.5 6 4.0 8.9 8.4 7.1 8.4 NA NA 
2002 15.6 12.0 5.1 6.3 9.3 9.7 6.0 11.7 NA NA 
2003 22.6 10.3 3.2 4.6 NA 9.1 12.5 14.0 3.9 2.3 
2004 11.9 13.6 10.3 9.0 NA 12.5 6.9 5.3 7.8 4.8 
2005 11.4 5.9 6.8 7.7 NA 10.6 7.1 11.2 5.3 4.0 
2006 17.3 9.5 4.9 7.7 NA 6.0 7.8 13.6 13.5 2.4 
2007 14.0 5.8 7.9 8.1 NA 18 9.3 7.7 9.1 6.7 
2008 10.2 5.6 7.1 9.8 NA 11.5 13.2 12.8 50 4.2 
2009 10.0 8.8 5.6 9.5 NA 11.1 5.0 17.2 10.9 3.3 
2010 17.2 5.6 8.8 5.8 NA 9.1 5.6 16.1 14.0 2.4 
2011 15.2 10.9 4.7 5.6 NA 8.3 11.6 13.6 12.5 5.9 
*New Jersey did not participate in NBDPS for study years 2003-11; North Carolina and Utah did not participate for study years 1997-2002 
*Arkansas and New Jersey did not have any eligible controls in 1997      
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APPENDIX B: SENSIVITY ANALYSES FOR PATERNAL CIGARETTE 
SMOKING AND MULTIPLE IMPUTATION 
A challenge in our Aim 2 analysis was limited information on paternal cigarette smoking 
during the 3-month preconception period, a hypothesized confounder. Paternal cigarette smoking 
was only ascertained during the second half of the study period (2007-2011), and is therefore 
missing for the first half of the study (~60% of eligible participants had missing paternal 
smoking). Our original analysis adjustment set did not include paternal smoking so as to 
maximize our study sample, but here we conduct sensitivity analyses to assess how paternal 
cigarette smoking may or may not impact our results.  
Table B.1 shows adjusted results under three scenarios: [1] fully adjusting (thereby 
excluding all observations with missing paternal smoking), [2] adjusting for everything except 
paternal cigarette smoking (thereby including observations with missing paternal smoking), and 
[3] adjusting for everything except paternal smoking but restricting to observations where 
paternal smoking is missing. Together, these three scenarios show how selection bias due to 
measured paternal cigarette smoking and confounding due to paternal cigarette smoking impact 
the paternal cannabis-birth defect effect estimates.  
Table B.2 shows results after multiple imputation of all missing confounder data 
(including imputation of the >60% paternal cigarette smoking variable). Imputation was 
conducted using PROC MI and PROC MI ANALYZE where data was imputed n=10 times and 
effect estimates were combined using Rubin’s rule. Results are displayed next to non-imputation 
adjusted results. 
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Table B.1. Sensitivity analysis of measurement and adjustment for paternal cigarette smoking, OR (95% CI) 
 Full study period Restricted to 2007-11 
Birth defect 
phenotype Crude Adjusted1 Adjusted2 Adjusted3 Adjusted1 Adjusted2 Adjusted3 
Non-heart 
defects           
Anencephaly 
and 
craniorachischisi
s 1.43 (1.11, 1.84) 0.99 (0.59, 1.67) 1.15 (0.80, 1.65) 1.04 (0.62, 1.74) 0.99 (0.59, 1.67) 1.04 (0.62, 1.74) 1.04 (0.62, 1.74) 
Spina bifida 0.93 (0.75, 1.15) 1.18 (0.81, 1.72) 1.02 (0.78, 1.33) 1.12 (0.77, 1.63) 1.18 (0.81, 1.72) 1.11 (0.76, 1.61) 1.12 (0.77, 1.63) 
Cleft palate 
alone 1.02 (0.84, 1.23) 0.86 (0.60, 1.25) 0.88 (0.69, 1.12) 0.82 (0.57, 1.18) 0.86 (0.60, 1.25) 0.82 (0.57, 1.17) 0.82 (0.57, 1.18) 
Cleft lip with 
cleft palate 1.21 (1.04, 1.43) 1.01 (0.74, 1.39) 1.06 (0.86,1.31) 1.02 (0.75, 1.40) 1.01 (0.74, 1.39) 1.02 (0.75, 1.40) 1.02 (0.75, 1.40) 
Cleft lip alone 1.34 (1.09, 1.63) 1.50 (1.02, 2.19)  1.23 (0.94, 1.60) 1.48 (1.02, 2.16) 1.50 (1.02, 2.19)  1.48 (1.01, 2.15) 1.48 (1.02, 2.16) 
Esophageal 
atresia 1.07 (0.83, 1.39) 1.19 (0.74, 1.93) 1.17 (0.84,1.63) 1.22 (0.76, 1.96) 1.19 (0.74, 1.93) 1.21 (0.75, 1.95) 1.22 (0.76, 1.96) 
Anorectal 
atresia/stenosis 1.00 (0.80, 1.25) 1.06 (0.70, 1.61) 1.18 (0.89, 1.56) 1.05 (0.69, 1.59) 1.06 (0.70, 1.61) 1.04 (0.69, 1.58) 1.05 (0.69, 1.59) 
Hypospadias 
second/third 
degree 0.96 (0.81, 1.13) 1.11 (0.81, 1.51) 1.05 (0.84, 1.32) 1.10 (0.81, 1.50) 1.11 (0.81, 1.51) 1.12 (0.82, 1.52) 1.10 (0.81, 1.50) 
Transverse limb 
deficiency 1.41 (1.11, 1.79) 1.52 (0.96, 2.41) 1.20 (0.87, 1.66) 1.41 (0.90, 2.20) 1.52 (0.96, 2.41) 1.47 (0.94, 2.30) 1.41 (0.90, 2.21) 
Craniosynostosis 0.77 (0.63, 0.95) 0.96 (0.66, 1.39) 0.92 (0.71, 1.20) 0.95 (0.66, 1.36) 0.96 (0.66, 1.39) 0.95 (0.66, 1.36) 0.95 (0.66, 1.36) 
Diaphragmatic 
hernia 1.28 (1.02, 1.61) 1.16 (0.73, 1.84) 1.33 (0.99, 1.79) 1.16 (0.73, 1.83) 1.16 (0.73, 1.84) 1.15 (0.73, 1.82) 1.16 (0.73, 1.83) 
Gastroschisis 3.07 (2.66, 3.54) 1.11 (0.83, 1.50) 1.25  (0.99, 1.58) 1.14 (0.85, 1.53) 1.11 (0.83, 1.50) 1.15 (0.86, 1.54) 1.14 (0.85, 1.53) 
Heart defects           
DTransposition 
of the great 
arteries 0.95 (0.72, 1.26) 0.85 (0.50, 1.43) 0.88 (0.62, 1.24) 0.83 (0.50, 1.38) 0.85 (0.50, 1.43) ** 0.83 (0.50, 1.38) 
Hypoplastic left 
heart syndrome 1.24 (0.95, 1.63) 1.53 (0.96, 2.42) 1.38 (0.99, 1.93) 1.59 (1.01, 2.50) 1.53 (0.96, 2.42) ** 1.59 (1.01, 2.50) 
RVOT defects 1.13 (0.96, 1.34) 1.21 (0.89, 1.64) 1.13 (0.91, 1.39) 1.20 (0.89, 1.62) 1.21 (0.89, 1.64) ** 1.20 (0.89, 1.62) 
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 Full study period Restricted to 2007-11 
Birth defect 
phenotype Crude Adjusted1 Adjusted2 Adjusted3 Adjusted1 Adjusted2 Adjusted3 
RVOT defects 
excluding 
Ebstein cases 1.13 (0.95, 1.34) 1.17 (0.85, 1.61) 1.14 (0.92, 1.41) 1.16 (0.85, 1.59) 1.17 (0.85, 1.61) ** 1.16 (0.85, 1.59) 
Pulmonary valve 
stenosis 1.08 (0.89, 1.31) 1.16 (0.81, 1.65) 1.11 (0.87, 1.41) 1.16 (0.82, 1.64) 1.16 (0.81, 1.65) ** 1.16 (0.82, 1.64) 
VSD 
perimembranous  1.07 (0.88, 1.30) 1.06 (0.59, 1.90) 0.98 (0.77, 1.24) 1.10 (0.62, 1.96) 1.06 (0.59, 1.90) ** 1.10 (0.62, 1.96) 
VSD muscular 0.90 (0.65, 1.24) 1.06 (0.57, 1.98) 0.88 (0.59, 1.29) 1.01 (0.55, 1.87) 1.06 (0.57, 1.98) ** 1.01 (0.55, 1.87) 
ASD secundum  1.15 (0.98, 1.35) 1.11 (0.81, 1.53) 1.06 (0.87, 1.29) 1.11 (0.82, 1.52) 1.11 (0.81, 1.53) ** 1.11 (0.82, 1.52) 
ASD NOS  1.30 (0.97, 1.73) 1.08 (0.47, 2.49) 0.70 (0.47, 1.04) 1.08 (0.47, 2.47) 1.08 (0.47, 2.49)  ** 1.08 (0.47, 2.47) 
*OR: odds ratio; CI: confidence interval; VSD: ventricular septal defect; ASD: atrial septal defect; NOS: not otherwise specified 
1 Fully adjusted (paternal cigarette smoking, other drug use, age, education; maternal cannabis use, other drug use,     
cigarette smoking, age, education, alcohol use, pregnancy intention, household income; study 
site) 
2 Adjusted for everything except paternal cigarette smoking 
3 Adjusted for everything except paternal cigarette smoking, where paternal smoking is not 
missing     
 
 
 
  
  
1
1
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Table B.2. Sensitivity analysis of multiple imputation of missing confounder data, OR (95% CI) 
Birth defect phenotype Crude Adjusted‡ Adjusted & Imputed† 
Non-heart defects     
Anencephaly and craniorachischisis 1.43 (1.11, 1.84) 1.15 (0.80, 1.65) 1.35 (0.97, 1.87) 
Spina bifida 0.93 (0.75, 1.15) 1.02 (0.78, 1.33) 0.93 (0.72, 1.20) 
Cleft palate alone 1.02 (0.84, 1.23) 0.88 (0.69, 1.12) 0.93 (0.74, 1.17) 
Cleft lip with cleft palate 1.21 (1.04, 1.43) 1.06 (0.86,1.31) 1.07 (0.88, 1.30) 
Cleft lip alone 1.34 (1.09, 1.63) 1.23 (0.94, 1.60) 1.27 (0.99, 1.63) 
Esophageal atresia 1.07 (0.83, 1.39) 1.17 (0.84,1.63) 1.16 (0.84, 1.59) 
Anorectal atresia/stenosis 1.00 (0.80, 1.25) 1.18 (0.89, 1.56) 1.06 (0.81, 1.39) 
Hypospadias second/third degree 0.96 (0.81, 1.13) 1.05 (0.84, 1.32) 1.16 (0.94, 1.43) 
Transverse limb deficiency 1.41 (1.11, 1.79) 1.20 (0.87, 1.66) 1.30 (0.97, 1.75) 
Craniosynostosis 0.77 (0.63, 0.95) 0.92 (0.71, 1.20) 0.98 (0.76, 1.27) 
Diaphragmatic hernia 1.28 (1.02, 1.61) 1.33 (0.99, 1.79) 1.41 (1.07, 1.86) 
Gastroschisis 3.07 (2.66, 3.54) 1.25  (0.99, 1.58) 1.26 (1.04, 1.53) 
Heart defects     
DTransposition of the great arteries 0.95 (0.72, 1.26) 0.88 (0.62, 1.24) 0.95 (0.68, 1.33) 
Hypoplastic left heart syndrome 1.24 (0.95, 1.63) 1.38 (0.99, 1.93) 1.27 (0.91, 1.77) 
RVOT defects 1.13 (0.96, 1.34) 1.13 (0.91, 1.39) 1.12 (0.92, 1.38) 
RVOT defects excluding Ebstein cases 1.13 (0.95, 1.34) 1.14 (0.92, 1.41) 1.13 (0.91, 1.39) 
Pulmonary valve stenosis 1.08 (0.89, 1.31) 1.11 (0.87, 1.41) 1.05 (0.83, 1.33) 
VSD perimembranous  1.07 (0.88, 1.30) 0.98 (0.77, 1.24) 1.05 (0.83, 1.33) 
VSD muscular 0.90 (0.65, 1.24) 0.88 (0.59, 1.29) 0.85 (0.57, 1.27) 
ASD secundum  1.15 (0.98, 1.35) 1.06 (0.87, 1.29) 1.06 (0.87, 1.29) 
ASD NOS  1.30 (0.97, 1.73) 0.70 (0.47, 1.04) 0.90 (0.62, 1.31) 
*OR: odds ratio; CI: confidence interval; VSD: ventricular septal defect; ASD: atrial septal defect; NOS: not otherwise specified 
‡ Adjusted for all confounders except paternal smoking; prior to multiple imputation 
† Adjusted for all confounders (including paternal cigarette smoking) after multiple imputation of all missing confounder data 
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